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Development of Small Molecule Neuroprotectants 
By Ashley G. Boice, Ph.D. 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
Virginia Commonwealth University, 2018. 
Major Director: Shijun Zhang Associate Professor, Department of Medicinal Chemistry 
 
Neurodegenerative diseases are a class of conditions that lead to progressive 
atrophy of different parts of the central nervous system (CNS). These diseases lead to 
devastating clinical outcomes to patients and give rise to an enormous socio-economical 
burden on society.1 One commonality among some of the most well-known 
neurodegenerative disorders, e.g. Alzheimer’s disease (AD), Parkinson’s disease (PD), 
and multiple sclerosis (MS), is neuroinflammation.2-4 Neuroinflammation stems from 
interactions of the innate immune system with toxins and insults to the central nervous 
system. In the case of irremovable or chronic insults and toxins, this leads to chronic 
damaging inflammation that hastens neuronal degeneration and exacerbates disease 
pathology.5,6 Recently, inflammasomes of the innate immune system have been indicated 
in playing essential roles in the observed inflammatory responses. The most studied 
inflammasome is the nod-like receptor pyrin containing 3 (NLRP3) inflammasome.7–9 
Recently our research group has successfully developed sulfonamide-based small 
molecule inhibitors of the NLRP3 inflammasome, such as JC-21 and JC-171, as potential 
xx 
 
therapeutics for AD and MS. Our studies established that JC-21 is a selective inhibitor of 
the NLRP3 inflammasome.10,11 Structural modifications led to the development of JC-171 
with improved pharmacokinetic properties. More importantly, our studies demonstrated 
the in vivo activity of JC-171 to effectively ameliorate the experimental autoimmune 
encephalomyelitis (EAE), a mouse model of MS.12 Our data also strongly suggested that 
inhibitors based on this chemical scaffold may directly target the NLRP3 
inflammasome.10–12 In this dissertation, we conducted biophysical, biochemical, and 
modeling studies to further elucidate the mechanistic information of these compounds as 
inhibitors of the NLRP3 inflammasome. In order to conduct further mechanistic studies, 
the NLRP3 protein was produced via transfection of HEK 293 cells with a modified 
plasmid of full-length human NLRP3 protein.13 Furthermore, LC-MS studies were 
conducted to confirm the blood-brain barrier penetration (BBB) of JC-171. Our studies 
established that JC-171 directly binds to the NLRP3 protein. The results also suggested 
that JC-171 may bind to the NACHT domain of NLRP3 while in a site that is distinct from 
the ATP binding site. This notion is supported by the fact that our compounds do not 
interfere with the ATPase activity of NLRP3. Docking studies of JC-171 to the homology 
model of the NACHT domain of NLRP3 also supported this assertion by showing the 
interaction of JC-171 with residues that are not overlapping with the ATP binding pocket. 
BBB penetration studies in combination with LC-MS analysis confirmed that JC-171 
shows better BBB penetration when compared to MCC950. Collectively, our results 
strongly support that our compounds function as NLRP3 inflammasome inhibitors by 
directly binding to the NLRP3 protein, a novel and distinct mechanism of action when 
compared to the known inhibitors that target the NLRP3 inflammasome pathway. These 
xxi 
 
results strongly encourage further development of such inhibitors as potential 
therapeutics for neurodegenerative diseases.
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Chapter 1: Introduction 
            Neurodegenerative diseases are a class of conditions that lead to progressive 
atrophy of different parts of the nervous system. These diseases can lead to a broad 
range of symptoms presented, from motor dysfunction in Parkinson’s disease (PD) to the 
significant cognitive decline seen in Alzheimer’s disease (AD). Various genetic mutations, 
toxins, insults, and autoimmune responses have been known to cause these ailments 
and the incidence of such diseases often increases with age. In addition to the detrimental 
effects to the health and well-being of the affected individuals, neurodegenerative 
diseases have become a growing concern as the healthcare costs are increasing as the 
senior population increases in numbers. 14,15 The most well-known neurodegenerative 
diseases are AD, PD, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).16 
AD, the most common type of dementia, is estimated to affect more than 5 million 
Americans of all ages in 2017 and up to 36 million individuals worldwide currently. It is 
predicted that  more than 88 million Americans will have AD by 2050.17 AD will cost  
Americans an estimated 277 billion dollars for the year 2018.18 The estimated occurrence 
of PD, the second most common neurodegenerative disease, in 2010 was approximately 
630,000 in the United states and is projected to double by 2040. Additionally, PD cost 
Americans more than 14.4 billion dollars in 2010.19 Finally, MS affects an estimated 
400,000 Americans and the least common but well known, ALS, affects an estimated 
30,000.20,21 Each neurodegenerative disease has its own distinct and comparably 
devastating clinical manifestations but based on the data presented the disease with the 
greatest socioeconomical burden is AD. 
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1.1 Alzheimer’s Disease 
1.1.1 AD History and Disease Presentation 
AD was discovered by Dr. Alois Alzheimer who examined a patient of Frankfurt 
Asylum who died of an undocumented mental illness characterized by memory loss, 
paranoia, and personality changes. In his examination, Dr. Alzheimer identified atrophy 
of the cerebral cortex and the abnormal histopathology including the deposits of neritic 
plaques and neurofibrillary tangles.22 Since then, the scientific community has made 
further progress in characterizing AD. AD is the most common form of dementia and 
accounts for 60 to 80% of all dementia cases.17 In early stages of the disease, the 
cognitive symptoms are milder and consist of episodic memory loss, taking longer to finish 
tasks, and increased anxiety. In moderate AD, the symptoms become more impactful and 
can include retrograde memory loss, paranoia, personality changes, difficulty with simple 
tasks, and getting lost. In severe AD, patients can lose the ability to communicate, have 
difficulty swallowing, and loss of bladder and bowel control.17,23 
 There are two types of AD, early-onset AD (EOAD) and late-onset AD (LOAD). Of 
all AD diagnoses, 10% are diagnosed with EOAD. Patients with EOAD begin to present 
with symptoms from as young as age 30 to 65. The main difference in the disease 
presentation of EOAD and LOAD is the increased frequency of  symptoms aside from 
memory impairment in EOAD, such as visual dysfunction, language impairment, and 
difficulty executing purposeful movements.24 The cause of these symptoms in EOAD is 
mutations to genes for either amyloid precursor protein (APP), presenilin-1 (PSEN1), or 
presenilin-2 (PSEN-2). A variant of apolipopotein E, apolipoprotein ε4, is also known to 
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increase susceptibility to the disease for LOAD or EOAD. 
 However,  the cause of LOAD is largely unknown but might be a combination of 
genetic risks and environmental factors.1,25 Some of these potential risk factors that have 
been investigated include air pollution,26 insecticide DDT,27 head injury,28 chronic 
inflammation, 29 and type 2 diabetes mellitus.30 Despite its prevalence and unclear cause, 
LOAD is not considered to be a part of the normal aging process. This being apparent 
from the similarities in both pathology and clinical presentation to EOAD.31 The 
devastating emotional, physical, and socioeconomical impact of AD has sparked an 
enormous effort of the scientific community to find an effective therapeutic treatment or 
cure for this disease. Without one certain cause in this multifactorial disease, multiple 
targets have been investigated 
based on the known histopathology. 
1.1.2 AD Histopathology 
The known histopathological 
changes in AD include toxic amyloid-
β (1-42) (Aβ42) oligomers and the 
fibrillar form of amyloid-β, which 
deposits of lead to the formation of 
neritic plaques.  Additionally, the 
disease is characterized by 
anomalously phosphorylated tau 
that forms filaments and lead to the 
buildup of neurofibrillary tangles. 
Figure 1.  The histopathology of AD in the brain 
compared with healthy brain. Adapted from Jin.34 
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With chronic sources of inflammation, glial scar formation from failed attempts correct 
these insults, and synaptic loss,32 in time, neurons fail to function properly or interact and 
eventually can lead to neuronal death. Neuronal death in AD frequently occurs with 
cholinergic neurons in the hippocampus and neocortex of the brain.33 With the increasing 
loss of dendrites, axons, and neurons, the brain shrinks.34,35 This atrophy of the brain 
becomes apparent as the cortex and hippocampus visibly shrink and the ventricles fill 
with fluid (Figure 1).34 To better understand these toxic insults that trigger the 
degeneration in the AD brain, further details on the two hallmarks, amyloid-β and  tau, 
need to be discussed. 
1.1.3 Aβ hypothesis  
 The first hypothesis to explain the pathology in AD, the amyloid cascade 
hypothesis (ACH), argues that amyloid-β peptide deposition in the brain is the triggering 
event leading to the pathology of AD. The major supporting evidence of this hypothesis 
is EOAD. Mutations to amyloid precursor protein (APP) and part of its gamma-secretase 
complex, presenilin, lead to AD 
pathology, directly connecting amyloid-β 
to AD.36 A key player in the hypothesis 
is APP, APP is a transmembrane protein 
with the larger N-terminal on the 
extracellular side of the membrane and 
the smaller C-terminal on the 
intracellular side. From knock-out and 
mutation studies, the function of the 
Figure 2.  The processing of APP. Adapted 
from Kaether and Haass.37 
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protein appears to be the maintenance of synapses and regulation of signaling the growth 
of dendrites and axons. APP can be cleaved by alpha-secretase to produce sAPP-alpha 
and C83. When cleaved by beta-site APP-cleaving enzyme 1 (BACE-1) it can produce 
sAPP-β and C99. C83 and C99 can then be further cleaved by gamma-secretase to 
produce P3 or amyloid-β, respectively, (Figure 2).37 The amyloidogenic pathway, 
following cleavage of C99 can produce amyloid-β at varying sizes but more frequently 
amyloid-β-40.38,39 
  Aβ42 is one of the most dangerous fragments because of its ability to form fibrils 
and oligomerize.40 The levels of soluble Aβ42 is associated with how severe AD is. Aβ42 
normally spreads throughout the neuronal tissue until it hits high enough levels that it then 
aggregates and forms fibrils and eventually plaques.38 It has been demonstrated that 
Aβ42 trimeric and tetrameric oligomers are the most dangerous. These can attach to 
synapses and lead to their dysfunction, and eventually lead to neuronal death.40 In order 
to investigate the effects Aβ42, in one study, researchers created an artificial plaque by 
the injection of pre-aggregated Aβ42 into the nucleus bacillus of Maynert (NBM) in the 
brains of rats. They concluded that the injection led to the formation of amyloid-β plaques, 
as well as astrocyte and microglial infiltration and activation. The injection also led to iNOS 
and COX-2 expression, interleukin-1-β (IL-1- β) production, cholinergic neuron death, and 
p38MAPK pathway activation. The artificial plaque produced demonstrated many 
characteristics of the plaques found in AD brains.41 amyloid-β fibrils and mutant APP are 
also linked to the formation of neurofibrillary tangles (NFT)  in transgenic mouse models 
in vivo.42–44 Despite the clear connection of deposition of amyloid-β to AD pathology, the 
ACH is not without its weaknesses. Some studies have indicated that both amyloid-β and 
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NFT may be a reaction instead of a cause. Similar AD pathology in regards to amyloid-β 
has been found in brains of survivors of traumatic brain injury (TBI)45,46 or with damage 
inflicted to the nucleus basalis of rats.47 Altogether, ACH is supported by ample data and 
a well-established hypothesis for the development of AD pathology.36 
1.1.4. Tau hypothesis 
The second hallmark of AD is NFT triggered by atypically phosphorylated tau. The 
tau hypothesis states that abnormally or hyper-phosphorylated tau is the causative event 
from which AD pathology originates. The major supporting evidence of this hypothesis is 
the strong correlation of the spread of tau pathology and the development of cognitive 
decline seen in AD.48 Specifically, the cognitive symptoms presented in AD patients 
correspond functionally to regions of the brain burdened by NFTs.49 Additionally, some 
studies have reported the presence of tau pathology before the deposition of the amyloid-
β peptide.50,51 The center of this hypothesis, tau, is a microtubule-associated cytoskeletal 
protein expressed throughout the CNS. Tau functions to regulate neurite outgrowth and 
stabilize microtubules. When tau is phosphorylated by kinases such as glycogen 
synthase kinase-3, its ability to stabilize microtubules is decreased.52 When tau is 
hyperphosphorylated, it detaches from the microtubule of the cytoskeleton; this creates 
paired helical filaments (PHFs) which triggers the formation of  neurofibrillary tangles that 
impede neuronal transport in AD and other tauopathies.53 The exact trigger which leads 
to tau hyperphosphorylation is not well established. However, studies have found multiple 
contributing factors. One study demonstrated that administration of cytokine IL-6 to 
hippocampal neurons could elicit an increase in the hyperphosphorylation of tau with 
dependence on cdk5/p35, which is a complex of cyclin-dependent kinase 5 and activator 
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p35. 54,55 Despite the distinct hypotheses, there have been unifying theories for the role 
in amyloid-β and NFTs in the pathology of AD that propose possible explanations for 
discrepancies in either theories. 48,56  
The involvement of both of these AD hallmarks and the failure of the immune 
system to correct these insults is the major contributing factor of the neuronal atrophy 
seen in AD. Additionally, they provoke a chronic and damaging cycle of inflammatory 
response from the innate immune system.2,57 
1.2 Multiple Sclerosis 
1.2.1 MS History and Disease Presentation 
 Between the late 1700s and early 1800s Multiple Sclerosis (MS) was first 
described in separate accounts by its clinical presentation and a depiction of its 
characteristic plaques by Robert Carswell and Jean Cruveilhier.58 It wasn’t classified as 
a distinct disease until 1868 when pathologist Jean-Martin Charcot connected the 
histopathological changes from autopsies of MS patients with their clinical symptoms.59,60 
Multiple sclerosis is an autoimmune disease characterized by sclerotic lesions in the brain 
and spinal cord. The clinical signs of the disease are limb weakness and numbness, 
bladder dysfunction, fatigue, depression, mood swings, and blurred vision. The disease 
is also often characterized by an exacerbation of symptoms with higher temperatures, 
known as Uhthoff’s phenomenon.20,61 There are multiple different types of MS which are 
distinguished by the progression of symptoms and the presence of relapses and 
remissions. The most common type of MS diagnosed in patients initially, 80%, is 
relapsing-remitting MS. This is characterized by symptoms lasting days to months 
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followed by remission in which a patient is symptom-free until the next relapse.62 The 
second type of MS, secondary-progressive, is defined by a slow progression in severity 
of symptoms and can include relapses. The third type of MS, primary-progressive, does 
not have relapses and remissions but instead a continuous progression of symptoms. 
Finally, 5% of patients initially diagnosed with MS are diagnosed with progressive-
relapsing MS. Progressive-relapsing MS, the rarest form of MS, is characterized by 
symptom flare-ups and a continuous decline and may or may not include remissions.63 
Risk factors for the development of MS include genetic mutations to the human leukocyte 
antigen (HLA) gene which encodes a cell surface antigen presenting protein (major 
histocompatibility complex)64 and  genes important for cytokine pathways such as 
interleukin-7 receptor.65 Another risk factor for MS is previous infection with the Epstein 
Barr virus.66 
1.2.2 MS Histopathology 
 MS is characterized by sclerotic plaques primarily in the white matter of the CNS. 
These lesions often occur in the corpus callosum, lateral ventricles, brain stem, optic 
nerves, and spinal cord.61 The plaques stem from the autoimmune demyelination of 
neurons. The myelin is a highly lipid-based multilayer sheath that protects the axons of 
neurons. The myelin sheath is produced and maintained by the oligodendrocyte glial cell. 
Gaps in the myelin are left to form the nodes of Ranvier which the electrical signal uses 
to travels down the axon by saltatory conduction.67 With demyelination, axonal injury or 
altered nodal components along axon lead to disrupted signal transduction. This then can 
lead to the symptoms seen during relapses in MS; symptoms continue until remyelination 
can occur.68,69 Other characteristics of lesions in MS are glial scarring around plaques to 
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block off inflamed tissue and infiltrated autoreactive leukocytes.68 Autoreactive leukocytes 
are recruited to the CNS by chemokines expressed during neuroinflammation.4 
1.3 The Immune System and Neurodegenerative Disorders 
 The commonality among these neurodegenerative disorders is neuroinflammation. 
Neuroinflammation is inflammation of the nervous system brought upon by the immune 
system in order to remove the agent causing damage and promote healing.2 When 
exposed to disease-specific trigger, immune cells are activated and release pro-
inflammatory factors. When chronically exposed to pro-inflammatory factors further 
neuronal dysfunction and damage occurs and leads to the release of damage-associated 
molecular patterns (DAMPs). DAMPs can then activate pattern recognition receptors 
(PRR) of the innate immune system and continue the cycle of damaging 
neuroinflammation.3,70 
1.3.1 The Immune System 
 The immune system is divided into 2 categories, the innate and the adaptive 
immune system. When confronted with foreign pathogens or damage, the innate immune 
system responds immediately with its defensive repertoire. This response is quick and is 
often not as specific as the adaptive immune system; damage and pathogens are 
recognized by their molecular patterns.71,72 There are multiple key components of innate 
immunity; one such category of innate immune cells are granulocytes which can release 
cytotoxic and pro-inflammatory substances.73 Another component is complement that 
functions to enhance phagocytosis of pathogens and damaged cells or form the 
membrane attack complex (MAC) which can rupture cell membranes.74,75 Additionally, 
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the natural killer cells support the innate immune system by the release of cytotoxic 
substances or by inducing apoptosis.72 Another important cell for the innate immune 
system is the macrophage, these large cells phagocytose cellular debris or pathogens as 
well as secrete pro-inflammatory factors.76 Finally, dendritic cells, which primarily function 
as antigen presenting cells,  can stimulate a response from the adaptive immune 
system.77  
The adaptive immune system serves to remember pathogens not already well 
recognized by the innate immune system. After antigen presenting cells reach the lymph 
nodes or spleen, this triggers the induction of clonal selection and expansion of B or T 
cells which recognize the antigen. Mature B cells main function is to produce antibodies 
to target pathogens for destruction or neutralization. T cells include  CD4+ helper T cells 
(Th) which regulate other immune cells and CD8+ cytotoxic T cells which can release 
cytotoxins to lyse pathogens or infected cells and induce apoptosis with Fas-Fas ligand 
interactions.78–80 These leukocytes recognize antigen presented on major 
histocompatibility complexes (MHC). CD4+ T cells recognize antigen presented by MHC 
type II by other leukocytes and CD8+ T cells can recognize antigen presented by MHC 
type I by any nucleated cells.81,82 Other adaptive leukocytes include: natural killer T cells, 
γδ T cells,72 regulatory B and T cells,83 and memory B and T cells.84,85 The innate and 
adaptive immune work together to protect the body from infection and disease. However, 
the immune system has limited access to some parts of the body. 
1.3.2 The Immune System in the Central Nervous System 
 The central nervous system (CNS) was first depicted as being immune privileged, 
meaning that the immune system has restricted access to the CNS. In the late 19th 
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century, Paul Ehrlick injected dyes intravenously and found that they stained all organs 
with the exception of the spinal cord and brain. The reason for this was in fact the blood 
brain barrier.86 In 1898, Ledwandowsky coined the term "blood-brain barrier," after he 
found that neurotoxic agents had an effect on the brain only when injected directly into it, 
instead of intravenously. 87 Multiple studies have demonstrated that the blood brain barrier 
(BBB) functions to limit the trafficking of ions, molecules, and cells. 94-90 However, the 
CNS is not completely immune privileged as it might appear;  the CNS has resident innate 
immune cells made up of glial cells and a lymphatics system that has been described.81 
Back in 1869 the lymphatic system in the brain was first described as an apparent 
connection between the brain and the cervical lymphatic system in rabbits and dogs.91 
Despite numerous other experiments in the 40s and 60s describing lymphatics in the 
brain,92,93 the idea that the brain was immune privileged persisted until more recent 
studies by Louveau and colleagues on mouse brain lymphatics and of human brain 
lymphatics by Reich were published.94,95 In addition to a lymphatic system, the brain has 
its own immune cells, glial cells.81,96 Glial cells are one of the main type of cells that make 
up the CNS and consist of microglia, oligodendrocytes, and astrocytes. They play 
important roles in the maintenance of neurons, production of myelin sheath, and 
protection of the CNS.96,97  
1.3.3 Microglial Cells 
  In 1919, the “father of microglia” Pio del Rio-Ortega demonstrated the distribution 
of microglia throughout the brain using silver carbonate and their ability to alter 
morphology when confronted with a disease state.98 Microglia cells have since then been 
described as the central nervous system’s first line of defense. They are important in 
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maintaining the homeostasis of tissues in the brain. They keep tabs on their environment 
seeking signs of disturbed functional or structural integrity. To maintain and protect the 
CNS, they can phagocytose worn-out cells, pathogens, or improperly formed synapses. 
However, they are also involved in the pathogenesis of neurodegenerative diseases like 
AD and MS.104-100In the AD brain, microglia are recruited from surrounding blood vessels. 
They migrate and gather into dense neritic plaques.101 Despite recruitment to the plaques, 
the number of microglial cells around the lesion does not correlate with amyloid-β 
degradation and instead it actually contributes to the volume of plaques. Instead of 
effectively executing their function, the removal of the insults, some studies report that 
they actually promote the converting amyloid-β oligomers in the plaques into fibrils 
(fibrillogenesis).32,102 Additionally, the microglia is involved in the pathogenesis of MS by 
demyelination of neurons and phagocytosis of myelin. Following the phagocytosis of 
myelin, the microglia further perpetuates MS pathology by antigen presentation to 
autoreactive T cells.103 
1.3.4 Astrocytes 
Astrocytes have many physiological functions in the innate immune system as well 
as structural. It is believed that they support the structure of the blood brain barrier, as 
their lengthy cytoplasmic extensions enclose capillaries in the brain. They also maintain 
homeostasis and regulate plasticity with the release of neurotransmitters and trophic 
factors. To combat pathologies, astrocytes undergo astrogliosis, altering both structure 
and function. When activated, astrocytes cease homeostasis maintenance duties and 
may evoke nerve cell damage.104–106 Multiple studies have shown that amyloid plaques 
and aggregated amyloid-β can activate astrocytes. The astrocytes then work to clear the 
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amyloid-β in the brain and take in Aβ42 into granules in their cytoplasm. They do this 
likely by either phagocytosis or endocytosis mediated by a receptor.105,107 Astrocytes also 
work to remove non-fibrillar amyloid with metalloproteases such as insulysin and 
neprilsin.57,108 The encasement and penetration of amyloid plaques by astrocytes with 
their cytoplasmic extensions can lead to scarring. The distribution of astrocytes within the 
cortex of AD brains appears to correlate with the breadth of the AD pathology.105 In MS, 
the astrocyte contributes to disease pathology by inhibition of remyelination by the 
formation of glial scar.103 Furthermore, activated astrocytes provide a source of cytotoxic 
factors.109  
1.3.5 Inflammation Signaling Pathway 
When the brain is confronted with damage or infection of any sort, the innate 
immune system uses inflammation as a defense. The purpose of inflammation is to 
remove harmful irritants and to halt their destructive effects. In the brain, what signals 
inflammation to occur is usually the accumulation of abnormal proteins or injured 
neurons.110,111 Glial cells, and neurons have a myriad of PRRs that recognize these 
DAMPs. These PRRs include  receptor for advanced glycation end-products (RAGE), rig-
like receptors (RLR), toll-like receptors (TLR), AIM2-like receptors (ALR), C-type lectin 
receptors, and NOD-like receptors.112 The signal transduction pathways triggered by 
these PRRs elicit inflammation.113 One example of these PRRs, TLRs, are receptors that 
can signal and activate protein kinases like p38-MAPK, IKKs, and JNK. These kinases 
spark inflammatory responses by transcription factors, such as IRF3/7, AP-1, and NF-
κB.114,115 These inflammatory responses include the secretion of chemokines, 
prostaglandins, oxygen radicals, and cytokines. Even though the purpose of inflammation 
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is to remove toxins and insults, this inflammatory response can be harmful to the brain in 
the case of chronic or irremovable insults.116-122  
1.3.6 Cytokines and Chemokines 
  Cytokines are important for inflammatory and anti-inflammatory processes. In 
general, anti-inflammatory cytokines antagonize the effects of pro-inflammatory 
cytokines, such as decreasing the synthesis of pro-inflammatory cytokines, inhibiting 
apoptosis, or inhibiting the secretion of harmful proteases like matrix metalloproteinases 
(MMP).  Anti-inflammatory cytokines include: IL-10, IL-4, and TGF-β-1.117 An imbalance 
of higher pro-inflammatory than anti-inflammatory cytokines can lead to the amplification 
of cytotoxic processes. If glial cells are activated for too long they can kill the neurons 
surrounding them by releasing toxic products, such as nitric oxide, excitotoxins, 
proteolytic enzymes like MMP, or reactive oxygen species (ROS).118  Pro-inflammatory 
cytokines secreted by glial cells can trigger this cycle and can activate complement 
cascades,  cyclooxygenase enzyme, and inducible nitric oxide synthase (iNOS). 
Additionally, activated microglia has been shown to produce chemokines, e.g., 
macrophage inflammatory protein-1alpha (MIP-1alpha), monocyte chemoattractant 
protein-1 (MCP-1), and IL-8.111 Chemokines are responsible for the recruitment of 
immune cells to the site of inflammation. Therefore, they are responsible for the extent or 
spread of the local inflammation.124,71 
1.3.7 Innate immunity and Inflammasomes  
One of the innate immune systems major contributors of proinflammatory 
cytokines is the inflammasome. The inflammasome is a highly regulated multi-component 
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PRR that responds to DAMPs or PAMPs for the purpose of protection against viral, 
bacterial, fungal, parasitic infections, or any disruption in homeostasis.119 However 
overactivation of the inflammasome is implicated multiple inflammatory diseases, such as 
familial cold autoinflammatory syndrome, type II diabetes mellitus, Crohn’s disease, and 
vitiligo-associated multiple autoimmune disease.120 Inflammasomes are characterized by 
the domains which they contain. PYHIN family of inflammasomes consist of DNA-binding 
HIN domain and an N-terminal pyrin (PYD) domain. This family includes the AIM2 and 
IFI16 inflammasomes.121 The NLR family, for example, contains a nucleotide 
oligomerization domain (NOD aka NACHT), a C-terminal leucine rich repeat (LRR) 
domain, and a variable N-terminal domain. The N-terminal domain can vary from a PYD 
domain in NLRPs to a caspase recruitment domain (CARD) in NLRC4. The NLR family 
inflammasomes include: NLRC4, NLRP1, NLRP2, NLRP3, NLRP6, NLRP7, and 
NLRP12.119 Inflammasomes without attached CARD use adapter protein apoptosis-
associated speck-like protein containing a caspase-recruitment domain (ASC) which 
contains both a PYD domain for associating with inflammasome and a CARD domain for 
caspase recruitment. With recruitment and activation of the caspase the inflammasome 
can cleave precursor cytokines into mature pro-inflammatory cytokines. The process is 
highly regulated, the inflammasome protein can be modified by phosphorylation and 
ubiquitination and requires a priming step to upregulate inflammasome components and 
precursor cytokines.25 Of the inflammasomes, the best characterized and most implicated 
in the progression of AD and MS is NLRP3.122-123 
1.3.8 The NLRP3 Inflammasome 
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Nod-like receptor pyrin containing 3 
inflammasome (NLRP3) belongs to the family of 
nucleotide oligomerization domain (NOD)-like receptors 
(NLR). NLRP3 consists of a LRR, NACHT, and PYD 
domain (Figure 3).9 NLRP3 inflammasome also includes 
the adaptor protein ASC and caspase-1. LRR functions 
as a sensor for DAMPs and PAMPs. In its autoinhibition 
conformation LRR interacts with the NACHT domain to 
prevent association with ASC.8 The NACHT domain is 
thought to play a role in oligomerization and has ATPase 
activity. ATP binds at a conserved site among NLRPs, 
the Walker A motif GxxxxGK(S/T). The NACHT domain also contains a Walker B motif 
necessary for ATP hydrolysis.124 The PYD domain mediates interaction with ASC and 
ASC recruits caspase-1 with CARD domain. NLRP3 inflammasome activation can occur 
in 2 ways canonical or non-canonical (Figure 4).125 
1.3.9 Activation of the NLRP3 Inflammasome 
In the canonical activation of NLRP3, the first step is the priming step for the 
upregulation of NLRP3 inflammasome components, pro-IL-1-β, and pro-IL-18 by the 
activation of NF-κB. Priming can occur via toll-like receptors (TLRs), such as MyD88 or 
TNFR with TLR agonists, agonists for NOD-like receptors, or CLR. Additionally, cytokines 
TNF-alpha and IL-1-β can also serve as priming promoters.126,127 The second step 
involves the activation of NLRP3. The LRR senses DAMPs or PAMPs. These signals 
include: extracellular ATP, potassium efflux, ROS, mitochondrial damage, pore-forming 
Figure 3.  The structure of 
NLRP3 inflammasome. 
Adapted from Lawlor et al.9 
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toxins, and nigericin. Another possible trigger for NLRP3 activation is the rupture of the 
lysosome. Rupture of the lysosome can occur after the phagocytosis of amyloid-β, 
aluminum salts, and silica crystals and is dependent on lysosome protease 
cathepsin.127,128 After activation, the LRRs interaction with the NACHT domain opens up 
and allows interaction with the PYD of ASC and ATP-dependent oligomerization. The 
PYD domain on NLRP3 recruits ASC and continues to do so as initiation of speck 
formation occurs. ASC nucleates caspase-1 filaments which then recruits local enzymes 
for trans-autocleavage of caspase-1 into subunits p10/p20 tetramer. Activated caspase-
Figure 4.  Canonical and non-canonical pathways of activation of the NLRP3 
inflammasome. Adapted from Man and Kanneganti.128 
 
18 
 
1 can then process pro-IL-1-β and pro-IL-18 into proinflammatory cytokines IL-1-β and IL-
18.8,129 
Non-canonical activation occurs when gram-negative bacteria activate TLRs which 
in turn activate NF-κB. In addition to transcription of the NLRP3 inflammasome 
components and cytokine precursors, interferon regulatory factors IRF-7 and IRF-3 genes 
are also transcribed. IRF-7 and IRF-3 then form a complex and trigger IFN-alpha/beta 
secretion. IFN-alpha/beta then activates the IFNAR1/IFNAR2 receptor which activates 
the JAK/STAT pathway, increasing the expression of pro-caspase-11. Activation of 
caspase-11 is not well established but it is believed that either procaspase-11 can be 
auto-activated on its own or the gram-negative bacteria activates a receptor which 
downstream can activate caspase-11. Activation of caspase-11 can then induce 
inflammatory cell death (pyroptosis) and activate the NLRP3 inflammasome caspase-1 
pathway.126,130 Another non-canonical pathway that may activate NLRP3 is via caspase-
8.  In some macrophages, after activation with fungal cell wall component, β-glucan, 
caspase-8 with Fas-associated death domain (FADD) can both prime and activate 
NLRP3.125 
1.3.10 Downstream Effects of Activation of the NLRP3 Inflammasome 
 Pro-inflammatory cytokine IL-1-β is of the major class of IL-1 cytokines. IL-1beta 
has been demonstrated to elicit inflammatory cascades through multiple pathways.  IL-1-
β can simulate inducible nitric oxide synthase (iNOS) via transcription factor NF-κB and 
CCAAT-enhancer binding protein (C/EBP) activation.131,132 It can also induce the 
production of granulocyte-macrophage colony-stimulating factor (GM-CSF).133,134 
Additionally, IL-1-β can trigger production of IL-6 which can then activate microglia, and 
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promote astrogliosis.135 The second cytokine produced by activation of NLRP3 
inflammasome, IL-18, is also a key player in neuroinflammation. This cytokine appears to 
exacerbate AD pathology by regulating the tau kinases GSK3-β and Cdk5. Additionally, 
levels of beta secretase enzyme BACE-1, subunit of gamma secretase n-terminal 
fragment of presenilin-1, APP, and adaptor protein Fe56 were found to be increased by 
IL-18.136 Furthermore, IL-18 can trigger production of interferon-gamma (IFN-gamma) 
from helper T-cells Th1.137 IFN-gamma, a pro-inflammatory cytokine can in turn induce 
production of nitric oxide.138 
1.3.11 Dysregulation of the NLRP3 Inflammasome in Neurodegenerative Disorders 
 Recently numerous studies have suggested the essential role of the NLRP3 
inflammasome in many human diseases including myocardial infarction, traumatic brain 
injury, diabetes type II, gout, AD, and MS. In an effort to better demonstrate the direct 
impact of NLRP3 inflammasome activation in these disease processes two well 
documented examples, AD and MS, will be briefly further discussed. 
 In AD, amyloid-β has been implicated to be a trigger for activation of NLRP3. In 
particular, soluble amyloid-β is phagocytosed by microglia leading to destabilization of 
the lysosome, releasing cathepsin B into the cytosol and triggering NLRP3 activation. 
Additionally, NLRP3 activation can occur when the amyloid-β oligomers elicit a potassium 
efflux from neurons.116 Aside from activation of NLRP3 by AD hallmarks, NLRP3 
inflammasome activation is implicated in the impediment of phagocytosis of amyloid-β by 
microglia. When microglia from APP/PS1/NLRP3 -/- were compared with microglia from 
APP/PS1 mice it was found that the microglia from the APP/PS1/NLRP3 -/- mice were 
significantly more efficient at phagocytosis of amyloid-β. Additionally, the level of amyloid-
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-β aggregates in APP/PS1/NLRP3 -/- were diminished without a change in total 
APP.139,140 
 Multiple Sclerosis is another neurodegenerative disease closely associated with 
the NLRP3 inflammasome.141 Caspase-1 and IL-1-β was found elevated in plaques in MS 
patients and elevated alongside cytokine IL-18 in peripheral blood mononuclear cells.145-
146,7 In experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, the 
NLRP3 inflammasome demonstrated a role in the recruitment of T-helper cells to the 
CNS.  NLRP3-/- mice displayed protection from development of EAE as well as 
decreased infiltration of T cells into the CNS. Th17 cells in these mice exhibited decreased 
expression of chemokine receptors CCR2 and CXCR6, important for infiltration of the 
CNS.147  
1.3.12 NLRP3 inflammasome as Novel Target for the Treatment of 
Neurodegenerative Disorders 
 Given the demonstrated role of NLRP3 
inflammasome dysregulation in the development of 
multiple human diseases, small molecules targeting 
the NLRP3 inflammasome pathway represents an 
innovative strategy to develop more effective 
treatments. Recently, several small molecule compounds have been reported to inhibit 
the NLRP3 inflammasome pathway. Acrylate derivative NLRP3 inhibitor demonstrated in 
vivo therapeutic potential for inflammatory bowel disease,144 ketone metabolite beta-
hydroxybutyrate a specific NLRP3 inhibitor which was shown to block ASC 
oligomerization,145 and selective NLRP3 inhibitor CY-09 which prevented death in a 
Figure 5.  Chemical structure 
of MCC950.147  
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mouse model of CAPs.146 The most potent however, MCC950, a diarylsulfonylurea 
compound, was discovered to  inhibit the processing of IL-1-beta (IC50 7.5 nM) (Figure 
5).147 Additionally, MCC950 demonstrated selectivity to NLRP3 among other 
inflammasomes by failing to inhibit IL-1-β secretion by AIM2 and NLRC4 after 
administration of selective activators dsDNA and bacteria Salmonella typhimurium to 
BMDMs respectively. Furthermore, MCC950 has shown effectiveness in vivo in a mouse 
model of Muckle-Wells Syndrome which is cryopyrin associated periodic syndrome 
(CAPS) that involves a mutation to NLRP3 and results in increased levels of IL-1-β and 
IL-18.151 In general, the exact mechanism of action of these NLRP3 inhibitors is not well 
established 
.       
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 Chapter 2: Preliminary Data 
2.1 Design of Sulfonamide-based Small Molecule Inhibitors of the NLRP3 
inflammasome  
Given the success of selective NLRP3 inflammasome 
inhibitors in in vivo models, the NLRP3 inflammasome appears 
to be a promising therapeutic target for the treatment of 
neuroinflammation. Recently, Glyburide, the commonly used 
anti-diabetic, has been shown to inhibit the NLRP3 
inflammasome.148 Glyburide 1, is a commonly used drug to 
treat type 2 diabetes, belonging to the class of sulfonylurea 
antidiabetics which also includes 
Glipizide 2 (Figure 6). Sulfonylurea 
antidiabetics treat diabetes by 
binding to and blocking K+ATP 
channels of the beta cells in the 
pancreas leading to depolarization 
of membrane and influx of calcium 
through Ca2+ channels. This 
triggers the exocytosis of insulin 
and subsequent lowering of blood 
sugar.149 When Glyburide was 
tested along-side the sulfonylurea antidiabetic drug, Glipizide, in mouse BMDMs, IL-18 
Figure 7.  Inhibition of the production of cytokines 
by glyburide and glipizide. BMDMs were primed 
with LPS and pre-incubated with drug and 
stimulated with ATP. A. IL-1β. B. IL-18. C. IL-6. 
D. TNFα. Adapted from Lamkanfi et al.148 
 
 
Figure 6.  Structures 
of Glyburide and 
Glipizide.148 
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and IL-1β were dose dependently inhibited, while TNF-
alpha and IL-6 were not suppressed by Glyburide 
treatments (Figure 7). This clearly indicated the specific 
inhibition of the NLRP3 inflammasome pathway by 
Glyburide. Notably, Glipizide did not show any effects 
on the production of IL-1β and IL-18 under the same 
experimental conditions. These results strongly 
suggested that the observed inhibition on the NLRP3 
inflammasome by Glyburide is independent from its 
anti-diabetic effects.   Additionally, Glyburide 
demonstrated dose dependent inhibition of cleavage of 
caspase-1, indicating prevention of the NLRP3 
inflammasome specific activation of caspase-1 
(Figure 8). In addition to presented data, the study 
also demonstrated that macrophage KATP channels 
and the cyclohexylurea moiety on Glyburide is not 
needed for inhibition of NLRP3, further supporting 
that the mechanism of action is not through its antidiabetic activity. Also, Glyburide 
inhibited the NLRP3 inflammasome independently of P2X7 receptor but appeared to act 
upstream of ASC and caspase-1 given that the activation of caspase-1 with adaptor ASC 
by other means (Ipaf and NALP1b) was not affected by glyburide. However, the dose of 
Figure 8.  Inhibition of 
production of caspase-1 
cleavage product p20. Black 
arrows indicate pro-caspase-1 
and white arrows indicate 
cleavage product p20. Adapted 
from Lamkanfi et al.148 
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glyburide needed to inhibit NLRP3 in vivo would result in lethal hypoglycemia, thus limiting 
further development of glyburide as a NLRP3 inflammasome inhibitor.148 
Based on the structure of glyburide, our group designed a 
sulfonamide analog, JC-21, and evaluated its inhibitory activity on 
the NLRP3 inflammasome (Figure 9). For the activity assay of 
caspase-1, HL-1 cells (immortalized mouse cardiomyocytes) were 
pretreated with JC-21 followed by priming with LPS and activation of 
the NLRP3 inflammasome with ATP. The caspase-1 activity was 
then determined by the cleavage of a fluorogenic substrate and 
cytotoxicity was determined with the Trypan blue exclusion method. 
The results demonstrated that JC-21 retained inhibitory activity on 
caspase-1 and rescued 
HL-1 cells from LPS/ATP 
treatment induced cell 
death (Figure 10). Our 
studies also established 
that JC-21 is a selective 
inhibitor to the NLRP3 
inflammasome as no 
activity was observed 
when NLRC4  
Figure 9.  
Structure of 
JC-21.11 
 
 
Figure 10.  Inhibition of caspase-1 activity and cell death 
by JC-21 A. Caspase-1 activity measure by CaspASE 
(Promega, Madison, WI). B. cell death determined by 
Trypan exclusion method. Adapted from Marchetti et al. 
11 
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or AIM2 inflammasome was activated with flagellin or poly-deoxyadenylic-
deoxythymidylic acid sodium salt (Poly(dA:dT)), respectively (Figure 11). Notably, our 
studies demonstrated that JC-21 inhibited the production of IL-1β from BMDM cells from 
NLRP3A350V/CreT transgenic mice. This specific mutation is heavily associated with Muckle-
Wells Syndrome (MWS) and Familial Cold Autoinflammatory Syndrome (FCAS), one of 
the cryopyrin-associated periodic syndromes (CAPS) characterized by overactivation of 
the NLRP3 inflammasome due to mutations to NLRP3. This mutant NLRP3 can 
spontaneously oligomerize into the active NLRP3 inflammasome without the need of 
activation signals. Collectively, the results from selectivity studies and the BMDMs 
carrying the mutant NLRP3 suggest that JC-21 may directly target the NLRP3 
inflammasome complex.10,11   
 
 
Figure 11.  Inhibition of caspase-1 activity and cell death by JC-21 given activators of 
inflammasome AIM2 and NLRC4. A. Caspase-1 activity measure by CaspASE 
(Promega). B. cell death determined by Trypan exclusion method. Adapted from 
Marchetti et al.11 
 
 
26 
 
2.2 JC-21 Analog, JC-171, Inhibits the NLRP3 Inflammasome 
Although JC-21 showed promising activity as a novel NLRP3 
inflammasome inhibitor, solubility was observed as an issue during 
the experiments. To improve aqueous solubility and also to evaluate 
whether structural modifications on the sulfonamide moiety are 
tolerated, a hydroxy group was introduced by the hydroxamic acid 
analog JC-171 (Figure 12). The Log P for JC-21 and JC-171 is 0.80 
and 0.19, respectively, confirming the increased polarity of JC-171. 
Our studies in mouse macrophage J774A.1 cells demonstrated a 
dose-dependent inhibition of IL-1β by treatment with JC-171 with an IC50 of 8.5 ± 1.6 μM 
but no inhibition of cytokines IL-6 and TNFα (Figure 13).12  
Prior studies employing constitutively active NLRP3 suggested that this chemical 
scaffold might function as an inhibitor by blocking the formation of the NLRP3 
Figure 13.  Inhibition of production of cytokines by JC-171. A. Dose-dependent 
response of inhibition of IL-1β. B. Inhibition of control cytokines IL-6 and TNFα. 
Adapted from Guo et al.12 
 
 
 
Figure 12. 
Structure of 
JC-171.12 
 
 
27 
 
inflammasome complex. In order 
to determine this, a co-
immunoprecipitation (IP) study 
was done using primary BMDMs 
stimulated with LPS and ATP. 
Shown in Figure 14, treatment of 
BMDMs with JC-171 blocked the 
association of ASC to the NLRP3 
protein during activation. This 
provided further evidence to the 
hypothesis that this novel chemical scaffold inhibits the NLRP3 inflammasome directly.12  
Considering neuroinflammation is a critical component of MS pathology and the 
demonstrated role of the NLRP3 inflammasome in MS,150–152 JC-171 was tested in 
experimental autoimmune encephalomyelitis (EAE), a mouse model of MS, for evidence 
that NLRP3 inhibitors can serve as potential 
therapeutic agents for MS. The therapeutic 
potency of JC-171 was tested alongside 
MCC950 by administration of either 
compound starting when the clinical scores 
of individual mice have reached 1 (flaccid 
tail). Subsequent clinical scores were 
assigned every other day based on the 
extent of paralysis of the mouse. Regardless 
Figure 14.  Inhibition of ASC association to 
NLRP3 by JC-171. NLRP3 and ASC were 
visualized via immunoblot (left). Ratio of band 
intensity of ASC to NLRP3 was calculated (right). 
Adapted from Guo et al. 12 
 
 
 
Figure 15. Clinical scores of EAE mice 
dosed with either 10 mg/kg of JC-171 
(green line), 10 mg/kg of MCC950 (red 
line), or vehicle (black line). Adapted 
from Guo et al.12 
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of the use of a low dose of JC-171 (10 mg/kg) in mice, 
JC-171 significantly attenuated EAE progression when 
compared with control (Figure 15).  JC-171 exhibited 
comparable in vivo therapeutic activity with MCC950, 
an NLRP3 inflammasome inhibitor that was recently 
reported to block EAE development.153 Additionally, 
treatment with JC-171 also led to a substantial 
decrease in the frequency of MOG35−55-specific Th17 
cells in both the spleen and spinal cords of EAE mice 
(Figure 16). Consistent with the reduction in clinical 
score, the histological analysis demonstrated that 
demyelination was reduced in the white matter of the 
spinal cords from EAE mice treated with JC-171, as 
indicated by Luxol fast blue staining (Figure 16). 
Collectively, the in vitro and in vivo results of JC-171 
and JC-21 suggest that this chemical scaffold is a 
promising template for the development of small 
molecule inhibitors for the NLRP3 inflammasome.11,12 Furthermore, this data also 
encourages the further development of JC-171 and analogues as potential therapeutic 
agents for MS as well as other inflammatory diseases involving the NLRP3 
inflammasome. 12 
 
 
Figure 16. Determination of 
demyelination of spinal cord 
and frequency of MOG 
specific Th17 cells in the 
spinal cord and spleen. A. The 
frequency of IL-17A+CD4+ 
Th17 cells in the spinal cord 
and spleen. B. Demyelination 
(indicated by black squares) in 
the spinal cord. Adapted from 
Guo et al.12 
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Chapter 3: Mechanistic Studies of Sulfonamide-based small molecule NLRP3 
inflammasome inhibitors 
Our studies suggested that analogs derived from this sulfonamide scaffold may 
directly interfere with the formation of the NLRP3 inflammasome complex. This was 
based on the fact that 1) inhibitors block ASC recruitment;12 2) they do not directly inhibit 
caspase-1 activation as NLRC4 and AIM2 pathways are not affected;11 and 3) they block 
the release of IL-1β and the activation of caspase-1 in macrophages expressing 
constitutively active NLRP3 from mutant mice.11,12 However, it is not clear how the 
inhibitors based on this chemical scaffold interfere with the formation of such protein 
complex. It is therefore our goal in this research project to elucidate the mechanism of 
action (MOA) for this chemical scaffold as direct NLRP3 inflammasome inhibitors by 
biophysical, biochemical and computational studies. Specifically, the microscale 
thermophoresis (MST) assay was utilized to determine the binding affinity of our 
compounds to various components of the NLRP3 inflammasome. Mechanistic studies 
involving the ATPase of the protein and molecular modeling were also employed to 
determine the possible binding site for our compounds. Finally, with liquid 
chromatography-mass spectrometry, the BBB penetration of our compound was 
measured. 
3.1 MST Assay 
3.1.1 Introduction to MST 
To measure the affinity of a direct interaction of our compounds with various 
components of the NLRP3 inflammasome, MST was employed. MCC950, a known 
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inhibitor that targets the NLRP3 inflammasome pathway was tested alongside our 
compounds to determine whether there was a shared MOA. As a relatively new 
technique, MST is used to quantify biomolecular binding interactions. MST uses a laser 
to create a thermal gradient in each capillary with fluorescently tagged-protein and varying 
concentrations of the non-labeled ligand or protein. The MST uses any change in 
thermophoresis caused by a change in the hydration shell around the fluorescent protein, 
change in size, charge, or conformation of the protein from binding interactions. Such 
binding interaction will change the movement of the protein in the thermal gradient and 
then can be detected by the fluorescence from the tagged-protein. Consequently, this 
enables a quantification of bound versus unbound protein to the ligand and therefore 
binding affinity (KD) of the ligand to protein can be calculated.154  
The binding check feature of the MST compares the normalized fluorescence 
(Fnorm) of labeled protein to the Fnorm of the labeled protein with ligand. Additionally, 
the binding check feature allows determination of any interfering fluorescence from buffer 
or ligand. The binding check can quickly determine if any binding can be detected without 
consuming as much protein as the binding affinity test. For the binding affinity test, the 
protein concentration is kept constant with 12 different concentrations of unlabeled ligand 
in each capillary. From the ∆Fnorm calculated in each capillary, a binding dependent 
sigmoidal curve should appear in the case of a binding event. The fraction bound can 
then be determined from the ∆Fnorm curve and a KD can be determined.154,155 
Initial fluorescence in each capillary is measured to ensure each value does not 
vary more than 10%. If initial fluorescence varies it could indicate either poor pipetting 
technique or ligand induced fluorescence changes; in either of these cases an accurate 
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KD cannot be determined.  Additionally, aggregation and adsorption to the capillary wall 
of the fluorescent protein is also determined to ensure a good quality sample. In addition 
to these automatic quality control checks, a few rules need to be applied when analyzing 
data to determine if the results can be reliably distinguished from noise. The amplitude of 
the noise in the baseline should be at the least 3 times less than the response amplitude 
between bound and unbound Fnorm values. Finally, as determined through 
experimentation with known binding interactions, the cut off response amplitude between 
bound and unbound should be ≥ 5 for reliable and reproducible results.155 
3.1.2 MST Results and Discussion 
3.1.2.1 Binding interaction with the recombinant and full length NLRP3 protein 
We first tested the binding interactions of JC-171 and MCC950 with human 
recombinant full-length NLRP3 protein by MST. The NT-647 labeled full length NLRP3 
protein was tested at a final concentration of 50 nM.  JC-171 was tested initially at 500 
μM with the binding check feature. The excitation was set to 40% for sufficient 
fluorescence counts and the power was set to medium for the best signal to noise ratio. 
The results revealed a response amplitude of 8.1 and a signal to noise ratio of 10. This 
clearly indicated a binding interaction between JC-171 and the NLRP3 protein. Following 
the binding check, a binding affinity assay of JC-171 to NLRP3 was then tested in triplicate 
at a range of 500 uM -122 nM. The results established a KD of 2.54 ± 0.500 μM, consistent 
with its IC50 for inhibition of the production of IL-1β. Notably, when MCC950 was tested 
in MST assays, no binding interaction was observed (Figure 17, 18). The results are in 
agreement with the published data to show that MCC950 does not interfere with NLRP3-
32 
 
NLRP3 interactions.153 The binding affinity results of JC-171 and MCC950 strongly 
suggest that they have distinct MOAs to inhibit the NLRP3 inflammasome. 
 
 
 
 
Figure 17. MST assay for affinity of JC-171 for fluorescently tagged (NT-647) full 
length NLRP3. A. Binding check for JC-171. B. Calculated fraction bound dose-
response of binding interaction of JC-171 and full length NLRP3. 
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3.1.2.2 Binding interaction with the mutant NLRP3 (K232A) Protein 
To further identify the binding domain within the NLRP3 protein for our compounds, 
a fluorescently labeled mutant NLRP3(K232A) was used to explore any change in binding 
Figure 18. MST assay for affinity of MCC950 for fluorescently tagged (NT-647) 
full length NLRP3. A. Binding check for MCC950. B. Calculated Fnorm dose-
response of MCC950. 
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affinity for JC-171.  K232 is one of the amino acids in the walker A motif of the nucleotide-
binding domain (NACHT). This amino acid coordinates with the gamma phosphate of 
ATP and is essential for ATPase activity.124 The binding check studies showed a  
   
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 19. MST assay for affinity of JC-171 for fluorescently tagged (NT-647) 
full length NLRP3 mutant (K232A). A. Binding check for JC-171. B. Calculated 
fraction bound dose-response of JC-171. 
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response amplitude > 5 and a signal to noise ratio of 5, suggesting binding interactions 
of JC-171 with NLRP3(K232A). Further binding affinity studies established a KD of 4.58 ± 
2.13 μM (Figure 19), comparable to the binding affinity from the full length NLRP3 protein. 
These results suggest that the binding site for our compound is not overlapping with the 
ATP binding site. 
3.1.2.3 Binding interaction with the LRR Component of the NLRP3 protein 
To further investigate which domain of NLRP3 our inhibitors might bind to, MST 
assays were conducted using the LRR fragment of the NLRP3 protein. In this study, the 
analogs of JC-171: GA3, HL-12, and HL-16 were tested for binding affinity. In our cellular 
assays, HL-12 and HL-16 are potent inhibitors on the release of IL-1β with IC50s of 0.670 
µM and 1.30 µM, respectively. Additionally, MCC950 was also tested for binding affinity. 
The NT-647 labeled LRR component of NLRP3 protein was used at a final concentration 
of 50 nM. The MST assay conditions were set identical to the ones used in full length 
NLRP3 protein. GA3 was tested in triplicate with a range of 1 mM to 0.15 uM (Figure 20). 
MCC950 was tested in triplicate at a range of 200 to 0.07uM (Figure 20). No binding 
interactions were observed for both GA3 and MCC950 under the current experimental 
conditions. This may suggest that our compounds do not bind to the LRR domain within 
the NLRP3 protein. Similarly, we did not detect binding interactions for analogs HL-12 
and HL-16 (Figure 21). Collectively, the results strongly suggest that there are no binding 
interactions for the tested compounds from our studies to the LRR domain of the NLRP3 
protein. 
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Figure 20. MST assay for affinity of GA3 and MCC950 for fluorescently tagged (NT-
647) NLRP3 LRR segment. A. Calculated Fnorm dose-response curves of GA3. B. 
Calculated Fnorm dose-response curves of MCC950 
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Figure 21. MST assay for affinity of JC-171 analogs for fluorescently tagged (NT-647) 
NLRP3 LRR segment. A. Calculated Fnorm dose-response curves of HL-12. B. 
Calculated Fnorm dose-response curves of HL-16. 
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3.1.2.4 Binding Interactions to the ASC Protein 
The NLRP3 inflammasome is a multiprotein complex with at least three proteins: 
NLRP3, ASC, and caspase-1. Since strong evidence has been presented to disregard 
Figure 22. MST assay for affinity of compounds for fluorescently tagged (NT-647) ASC 
protein. A. Calculated Fnorm dose-response curves of GA3 from MST assay. B. 
Calculated Fnorm dose-response curves of MCC950 from MST assay. 
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binding interactions with caspase-1 as the MOA, further investigation into the binding 
interactions with ASC was investigated to better establish that interaction with ASC was 
not the MOA of our compounds. To evaluate whether our compounds bind to the adapter 
protein ASC, MST studies were conducted for GA3 and MCC950. The NT-647 labeled 
ASC protein was tested at a final concentration of 10 nM. The MST excitation was set to 
95% for sufficient fluorescence counts and the MST power was set to medium for the best 
signal to noise ratio. As shown in Figure 22, a binding curve might be observed for GA3 
to ASC protein. However, the response amplitudes remained below 5 and poor signal to 
noise ratios were observed. This indicated that the signals could not be distinguished from 
noise. MCC950 was also tested in a range of 200 to 0.07 uM and no binding interaction 
was observed as well under the experimental conditions (Figure 22). 
3.2 Direct Binding to NLRP3 
In the interest of supporting data for direct binding to the NLRP3 protein as being 
the mechanism of action of the compound, a 
pull-down assay coupled with immunoblotting 
was performed by Dr. Liu He. J774A.1 primary 
mouse macrophage cells were pretreated with 
LPS to induce production of NLRP3 protein. Cell 
lysates were incubated with control compound 
CY-09-probe, a positive control that 
demonstrated ability to bind to NLRP3 in pull 
down assay,146 or a biotin conjugated probe 
analog of JC-171 compound, HL-79. Lysates 
Figure 23. Immunoblot of J774A.1 
lysate incubated with biotin probes 
of CY-09 or JC-171 analog (HL-79) 
using antibody specific for NLRP3. 
Positive control is CY-09 probe 
known to bind to NLRP3 and 
negative control is cell lysates 
without probe. 
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were incubated with beads to capture biotin probes, washed, and then boiled and 
resultant protein run on SDS-PAGE followed by an immunoblot with primary antibody for 
NLRP3 and secondary antibody with attached HRP for visualization (Figure 23). HL-79 
probe captured NLRP3 better at 1 μM than positive control CY-09 probe at 5 μM. This 
data further supported direct interaction with the NLRP3 protein as being the mechanism 
of action of these compounds for inhibition of the NLRP3 inflammasome. 
3.3 ATPase activity of the NLRP3 protein 
3.3.1 Introduction to the NLRP3 ATPase 
Due to the conserved nature of the ATP binding pocket among the NACHT 
domains of inflammasomes, it would be of importance to determine whether our 
compounds interfere with the ATPase activity of NLRP3, given the fact that our binding 
studies strongly suggest the interaction of our compounds with the NACHT domain. The 
ATPase activity study will also support the results of the binding interaction of JC-171 to 
the mutant NLRP3 (K232A). Furthermore, despite the importance of K232 to ATP binding, 
other conserved residues are also involved in ATP binding of the walker A motif.156 
Therefore, the investigation of the ATPase interference by our inhibitors will provide 
valuable information on whether or not there is any interaction with our compounds and 
the ATP binding pocket. In order to determine the ATPase activity of NLRP3 protein, the 
ADP-Glo assay (Promega, Madison, WI) was employed. 
3.3.2 ADP-Glo Results and Discussion  
After incubation of compounds with human recombinant NLRP3 protein following 
references protocol,144 ATP was the added for hydrolysis. The positive control contained 
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only protein and ATP to determine the percent conversion of ATP to ADP. The negative 
control was a blank with no protein or ATP to determine if there was any background 
signal.  A standard curve of ATP and ADP from 250 uM of ADP (100% conversion) to 0 
uM of ADP (0% conversion) and the corresponding concentrations of ATP 0 uM to 250 
uM was established (Figure 24). The r² of the fit was > 0.991. The assay was done in 
triplicate alongside a standard curve for each repeat and the signal from the samples was 
normalized as a percentage of the positive control to better visualize percent inhibition of 
the ATPase.  
 
As shown in Figure 25, no inhibition on the ATPase activity of NLRP3 was observed for 
all of the tested compounds. Combining the results of binding interaction with mutant 
NLRP3 (K232A), the results suggest that our compounds do not bind to the ATP binding 
Figure 24. Representative standard curve tested samples from one assay of the 
triplicate performed. The equation for the fit and r² are displayed in the upper right-
hand corner of the graph. 
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pocket within the NLRP3 protein. However, our results suggested a relatively low 
conversion rate of ATP (≤ 5%) by the ATPase of NLRP3 under the current experimental 
conditions. Further testing is warranted with a higher concentration of NLRP3 to decisively 
conclude none of the compounds interfere with the ATPase activity. 
 
3.4 Molecular Modeling studies 
3.4.1 Introduction to Molecular Modeling of the NLRP3 Protein 
 The protein binding experiments and ATPase activity studies indicated that JC-
171 binds to the NLRP3 protein but not to the adaptor protein ASC of the NLRP3 
inflammasome. The results further suggested that our compound may bind to the NACHT 
0
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Figure 25. ADP-Glo assay to determine inhibition of ATPase activity of the NLRP3 protein by 
JC-171 and other analogs. Luminescence signals were normalized as percentage of the 
positive control. 
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domain of NLRP3 protein, but without interfering with ATP binding. To further support this 
conclusion and visualize the possible binding sites of our compounds to the NACHT 
domain of NLRP3, a homology model of the NACHT domain was constructed from the X-
ray crystal structure of NLRC4 with MODELLER.157,158 NLRC4, Nod-like receptor card 
domain containing protein, is another member of the NLR family that recruits caspase-1. 
Unlike NLRP3, NLRC4 contains an N-terminal CARD domain. Additionally, NLRC4 
inflammasome is activated by flagellin and type III secretion systems of gram negative 
bacteria instead of extracellular ATP and other DAMPs that activate NLRP3.159 The 
structure of NLRC4 was chosen mainly based on the sequence identity and similarity of 
its NACHT domain to the NACHT domain of NLRP3 protein. Homology models generated 
using template structure were filtered by Ramachandran plots. To further validate the 
model, ADP from the crystal structure was docked back into the nucleotide binding pocket 
of the model and HINT scores calculated to determine if hydropathic interactions were 
favorable.160 JC-171 was docked with GOLD and HINT score was calculated to gauge if 
the interaction was favorable.161 
3.4.2 Results and Discussion 
3.4.2.1 Sequence Alignment 
The sequence alignment was conducted using emboss needle pairwise sequence 
alignment. This sequence alignment program uses the Needleman-Wunsch alignment 
algorithm to identify the best alignment over entire length of the sequences. The results 
demonstrated an identity of 24.1% and similarity of 41.2%.  Gaps were measured to be 
19.4% and the score was 161.162 The score is the sum of matches minus the penalty for 
gaps opened (Figure 26). The percentage of identity does not meet the rule of thumb for 
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homologs, which is ≥ 30%.163 However, it is well established that these two proteins are 
related through the NLR family and the NACHT domains of both proteins are share similar 
functions.129 Furthermore, when the sequences of the ATP binding pocket of these 
proteins compared, the alignment showed a sequence identity of 50% and a similarity of 
75%. The alignment was therefore used to generate homology models through 
MODELLER.157 
Figure 26. Sequence alignment of mouse NLRC4 NACHT domain with human NLRP3 
NACHT domain by emboss needle pairwise sequence alignment. Identical amino acids 
between the sequences are indicated with a dark grey box. Light grey boxes are used to 
indicate similar amino acids between the sequence. 
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3.4.2.2. Structure and Validation 
The models were compared by Ramachandran plots. A Ramachandran plot is 
important for determining the structure and conformation of the protein by comparing the 
dihedral angles between Cα and C (ψ) and between N and Cα (φ) of the backbone of the 
protein. Model 70 indicated a beta sheet and right-alpha helix structure and had some 
indication of left-handed alpha helix 
structure. The model in general is 
comparable to the Ramachandran 
plot of template structure NLRC4 
and had few violations (Figure 27). 
The models with the best 
Ramachandran plots were next 
compared by docking the ADP from 
the crystal structure of NLRC4 back 
into the nucleotide binding pocket 
(Figure 28). In model 70, ADP 
formed H-bond interactions with 
amino acids Lysine 232, Threonine 
233, Glycine 229, Histidine 522, and 
Arginine 351 (Figure 29). 
Specifically, the beta phosphate of 
ADP formed H-bond interactions 
with Lysine 232, Glycine 229, and 
Figure 27. Ramachandran plots of NACHT 
domain. A. NACHT domain of NLRC4. B. 
Homology model 70 of NACHT domain of 
NLRP3. Red dots indicate violations compared 
to ideal.  
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Histidine 522. The alpha phosphate formed H-bond interactions with Lysine 232, 
Threonine 233, and Arginine 351. Amino acids Lysine 232, Threonine 233, and Glycine 
229 correspond with the amino acids Lysine 175, Serine 176, and Glycine 172 of the 
NLRC4 nucleotide binding pocket where ADP forms interactions within the template 
crystal structure. Another amino acid that ADP binds to in model 70, Histidine 522, 
corresponds with the amino acid Histidine 443 in the structure of NLRC4 to which ADP 
binds.158 Histidine 522 is a conserved amino acid in the winged helix domain of NACHT 
domain and has been suggested to 
be important for the stabilization of 
the autoinhibition conformation.124 In 
addition to interactions with the 
walker A motif and winged helix 
domain, ADP formed a H-bond 
interaction with Arginine 351 of the 
highly conserved sensor 1 motif. This 
motif is believed to coordinate with 
the nucleotide binding.15 In addition to 
forming hydrogen bonds with 
important amino acids for nucleotide 
binding, ADP also demonstrated 
favorable hydropathic interactions 
with a HINT score of 5,814.160  Interactions that contributed to this score were: 5.468e+03 
for hydrogen bonds, 6.442e+03 for acid/base interactions, and 1.257e+03 for hydrophobic 
Figure 28. ADP docked in the ATP binding 
pocket of homology model 70. ADP is 
indicated in red.  
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interactions. Unfavorable interactions that contributed to this score were: -1.499e+03 for 
acid/acid interactions, -1.766e+03 for base/base interactions, and -4.087e+03 
hydrophobic/polar interactions. Based on these observations, Model 70 was chosen for 
further docking studies. 
 
3.4.2.3 Docking studies of JC-171 and other analogs 
JC-171 and other analogs were docked into model 70 with GOLD v. 5.4. The 
binding pocket in which the analogs consistently docked with the highest CHEMPLP 
scores was located next to the nucleotide binding domain. Although this domain does not 
overlap entirely with the ADP binding pocket, it does share one amino acid at the edge of 
the binding pocket, Arginine 351 of the sensor 1 motif (Figure 30). Other amino acids that 
formed H-bond interactions with JC-171 were Arginine 237, Glutamine 509, and 
Isoleucine 521 (Figure 31). The CHEMPLP for JC-171 docked in the pocket was 70.53.161 
The HINT score was calculated as 880.6.160 Favorable interactions that contributed to this 
score include: 2.247e+03 from acid/base interactions, 9.323e+02 from hydrogen bond 
Figure 29. ADP docked into ATP binding pocket. ADP interacted with amino acids of 
the Walker A motif: Glycine 229, Lysine 232, and Threonine 233. ADP also formed 
hydrogen bond with conserved amino acid Arginine 351 of the sensor 1 motif, and 
Histidine 522. 
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interactions, and 4.830e+02 from hydrophobic interactions. Unfavorable interactions that 
contributed to this score include: -1.569e+03 hydrophobic/polar interactions, -9.325e+02 
base/base interactions, and -2.808e+02 acid/acid interactions. 
Although Arginine 351 has been implicated to coordinate with the nucleotide in 
ATP binding, it’s role in ATP binding to the NLRP3 protein is not well established.124 Due 
to its close proximity to the ATP binding pocket and interaction with the winged helix 
domain, the binding pocket where JC-171 and other analogs docked into may represent 
an allosteric site that supports the autoinhibition conformation and prevents 
oligomerization of the NACHT domain.15 Although close to the nucleotide binding pocket, 
JC-171 does not bind in the binding pocket or to any amino acids in the Walker A motif. 
This is consistent with the MST binding results of JC-171 with mutant NLRP3 (K232A). 
Figure 30. JC-171 docked into the pocket next to nucleotide binding pocket. Walker A 
motif highlighted in red. ADP is depicted as orange molecule and JC-171 is depicted 
as cyan molecule.  
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The binding of JC-171 to Arginine 351 does not conclusively assert that JC-171 should 
inhibit ATPase activity, especially given the unclear role of this residue in ATP binding. 
But this does raise the question that a higher concentration of NLRP3 protein and/or 
robust ATPase activity needs to be investigated to rule out the possibility that JC-171 will 
interfere with the ATPase activity of NLRP3 protein.  
 
 
 
 
 
 
 
3.5 Production of NLRP3 protein 
3.5.1 Plasmid Preparation 
Given the promising results from the binding interaction, modeling, and 
biochemical studies, and also the need to further characterize the ATPase activity, we 
decided to engineer human full length NLRP3 proteins, with the expertise of collaborator 
Dr. Darrell Peterson, to further support our studies and facilitate the discovery of more 
Figure 31. JC-171 binding interactions within binding pocket of the NACHT domain. 
Hydrogen bonds were formed with amino acids: Arginine 237, Arginine 351, Glutamine 
509, and Isoleucine 521. 
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potent analogs. To accomplish this, a full length human NLRP3 protein with pEGFP-C2 
vector for mammalian expression was obtained (Figure 32).13  To facilitate purification 
process, a His-tag was introduced to the sequence by the polymerase chain reaction 
(PCR) technique with a forward primer containing a sequence encoding a His-tag. 
Unfortunately, the attempt with PCR for the full sequence with the primer encoding His-
tag did not succeed. The sequence was re-examined for possible restriction sites that 
could be utilized to synthesize the sequence in parts (Figure 33). Restriction sites are 
palindromic sequences that specific restriction enzymes can recognize and cleave. 
Cleavage of the double stranded DNA then leaves an over-hang DNA which can then be 
Figure 32. pEGFP-C2 vector with full length human NLRP3 protein insert. 
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ligated to the complementary sequence from the same restriction site.164 To determine 
which pieces could be synthesized, forward and reverse primers were used to generate 
these fragments: NheI/SacI, SacI/BamHI, BamHI/EcoR1, EcoR1/XhoI, NheI/BamHI, 
EcoR1/XhoI, BamHI/XhoI, and SacI/EcoR1. 
           NheI        
      ggatgctagcatgcaccatcaccatcaccatgcaagcacccgctgcaagctggccagg  
ggatgctagcatgcatcaccatcaccatcacaagatggcaagcacccgctgcaagctggccaggtacctggagga   
cctacgatcgtacgtagtggtagtggtagtgttctaccgttcgtgggcgacgttcgaccggtccatggacctcct 
75                                                                                                                                                                                                                                                                                        
                                            SacI 
caagaccaagacgtgtgagagccccgtgagtcccattaagatggagctcctgtttgaccccgatgatgagcattc  
gttctggttctgcacactctcggggcactcagggtaattctacctcgaggacaaactggggctactactcgtaag 
675 
                                    XmaI                                                                                                   
ggtgtacgtcttcttcctttccagtttgctgcagccccggggagggagccaggagcacggcctctgcgcccacct  
ccacatgcagaagaaggaaaggtcaaacgacgtcggggcccctccctcggtcctcgtgccggagacgcgggtgga 
1425                                                                     
                    BamHI 
aggaaggacgaacgttccaggatcccgtttgaagcttcccagccgagacgtgacagtccttctggaaaactatgg  
tccttcctgcttgcaaggtcctagggcaaacttcgaagggtcggctctgcactgtcaggaagaccttttgatacc 
1725                  
                        BglII                                               
cttggagaagaaattaagttgcaagatctctcagcaaatcaggctggagctgctgaaatggattgaagtgaaagc  
gaacctcttctttaattcaacgttctagagagtcgtttagtccgacctcgacgactttacctaacttcactttcg 
1875                                                                                                                                                             
                                                         EcoRI 
aattttatgtgaaaaagccaagaatccacagtgtaacctgcagaaactggggttggtgaattctggccttacgtc  
ttaaaatacactttttcggttcttaggtgtcacattggacgtctttgaccccaaccacttaagaccggaatgcag 
2550                                            
                                            XhoI 
agaaaagcctgagctgaccgtcgtctttgagccttcttggtagctcgaggc    
tcttttcggactcgactggcagcagaaactcggaagaaccatcgagctccg  29274 
 The PCR experiments were performed with 30 cycles for amplification in a 
thermocycler. PCR products were visualized by agarose gel electrophoresis, a common 
technique to visualize and separate DNA fragments by size. As shown in Figure 34, the 
largest piece that was successfully synthesized by PCR was NheI/BamHI with 1,670 base 
pairs. The other piece BamHI/XhoI with 1,304 base pairs was successfully identified the 
second attempt with PCR (Figure 34). The primers used to synthesize these pieces were  
Figure 33. The insert sequence with found restriction sites highlighted and labeled. 
DNA sequence number is indicated in bold at the end of each segment. 
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forward primers: NheI/BamHI 5'-ggatgctagcatgcaccatcaccatcaccatgcaagcacccgctgca 
agctggccagg-3’ and BamHI/XhoI 5’-caggatcccgtttgaagcttcccagccgagacgtg-3’. The 
reverse primers to make these pieces were: BamHI/NheI 5’-ggggatcctggaacgttcgtcc 
ttccttccttttcctc-3’ and XhoI/BamHI 5’-gcctcgagctaccaagaaggctc aaagacgacgg-3’. The 
PCR products for Nhe1/BamHI and BamHI/XhoI were recovered with Qiaquick gel 
extraction kit. The expression vector used for NheI/BamHI and BamHI/XhoI was 
expression vector pcDNA 3.1/Hygro that has all three necessary restriction sites (Figure 
35).165 NheI/BamHI and BamHI/XhoI and their corresponding vectors were ligated 
together and transformed into BL21 (DE3) competent E. coli cells. The cloned plasmids 
were collected then digested with appropriate enzymes and visualized on agarose gel. 
 
Figure 34. PCR products run on agarose gel. (Left) PCR products for pieces: 
NheI/SacI, SacI/BamHI, BamHI/EcoR1, EcoR1/XhoI, NheI/BamHI, EcoR1/XhoI, 
BamHI/XhoI, and SacI/EcoR1. (Right) Second PCR attempt at BamHI/XhoI. 
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As shown in Figure 36, the clones showed individual inserts. Inserts were then sequenced 
(Figure 37).  
  Purified plasmid with BamHI/XhoI 
insert was digested with NheI and BamHI 
restriction enzymes. The insert from the 
plasmid with NheI/BamHI was then ligated 
into vector with BamHI/XhoI insert. The 
newly formed plasmid with entire sequence 
was then transformed back into competent 
bacterial cells. Qiagen mini-preps were 
done for 4 bacterial colonies (Qiagen, 
Hilden, Germany). 
Figure 35. pcDNA 3.1/Hygro mammailian expression vector with necessary restriction 
sites indicated in red circles. 
 
Figure 36. Cloned pcDNA 3.1/Hygro+ 
inserts digested with appropriate 
enzymes. (Left) Cloned vector + 
BamHI/XhoI insert. (Right) Cloned 
vector + NheI/BamHI insert. 
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 Plasmids collected from 4 colonies were digested with 2 different sets of restriction 
enzymes, NheI/XhoI or BamHI/XhoI enzymes. Colonies 1-3 had the correct inserts for 
NheI/XhoI and BamHI/XhoI. However, colony 4 did not have the correct NheI/XhoI insert 
so was discarded (Figure 38). Diluted pooled plasmid was tested for absorption at 280 
nm and 260 nm with UV-vis spectrophotometer to estimate the concentration of the 
Figure 37. Cloned pcDNA 3.1/Hygro+ inserts sequenced. (Top sequence) The 
sequence from insert NheI/BamHI insert. (Bottom sequence) The sequence from insert 
BamHI/XhoI. 
 
55 
 
plasmid and determine how much bacteria was 
needed to make enough plasmid for transfection 
and determine the purity of the sample. 
The UV-vis spectrophotometer reading detected 
0.517 AU for 280 nm and 0.914 AU for 260 nm.  This 
gave a ratio of 1.77 indicating the nucleic acid 
content was quite pure. Using the extinction 
coefficient and Beer-Lambert’s law the 
concentration of plasmid 
was estimate to be 457 
ug/ml. From this it was 
determined how much 
more bacteria needed to 
be used to clone enough 
plasmid.  
Plasmids were again collected and purified with and cut 
with restriction enzyme pairs: NheI/XhoI, NheI/BamHI, and 
BamHI/XhoI. These digested plasmids were then visualized 
on agarose gel (Figure 39). When digested with enzymes 
for the full sequence, NheI/XhoI, or enzymes for either 
NheI/BamHI and BamHI/XhoI piece, the resulting pieces 
analyzed by agarose gel were the correct size. The plasmid 
produced was enough for transfection. 
Figure 38. Colonies 1-4 of 
cloned pcDNA 3.1/Hygro+ full 
NLRP3 sequence cut with either 
NheI and XhoI restriction 
enzymes or BamHI and XhoI 
restriction enzymes. 
 
Figure 39. Purified 
colony of pcDNA 
3.1/Hygro+ full NLRP3 
sequence. Plasmids 
were either cut with 
either NheI and XhoI 
restriction enzymes, 
NheI and BamHI, or 
BamHI and XhoI 
restriction enzymes. 
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3.5.2 Transfection 
Human embryonic kidney 293 cells 
(HEK-293) were transfected with plasmid 
using ExpiFectamine TM 293 kit 
(ThermoFisher Scientific, Waltham, MA). As 
shown in Figure 40, the optimal time for 
protein expression were days 1-3, after which 
the expression of NLRP3 protein decreased 
due to reduced cell viability. Collectively our 
results confirmed that we can successfully 
express full length NLRP3 proteins to support 
our continuning studies. 
3.6 LC-MS 
3.6.1 Method development 
To evaluate the ability of our compound to penetrate the BBB and compare to the 
potent NLRP3 inhibitor with comparable therapeutic in vivo MS mouse models, MCC950, 
LC-MS was utilized. In order to quantify the concentration of compounds in the brain 
samples, first a reliable method had to be established. To help with precision and account 
for matrix effects, Glipizide, another sulfonamide small-molecule compound, was chosen 
as the internal standard. Glipizide proved stable and flexible in terms of ionization. 
Both positive and negative ion modes of ESI were tested for detection of each 
compound. However, it was determined that separate ionization modes needed to be 
Figure 40. Immunoblot of HEK 293 
cells transfected with pcDNA 
3.1/Hygro+ full NLRP3 sequence. 
NLRP3 visualized with anti-NLRP3 and 
secondary antibody anti-rabbit IgG with 
conjugated HRP. 
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used for each compound for detection. Negative ionization mode of ESI was used for 
MCC950; the reason for the better signal in this mode was that the compound was 
purchased as a salt with a negative charge on the nitrogen of the sulfonamide group. JC-
171 (GA4), however, gave a better signal in positive ion mode due to its amine. 
Conveniently, the internal standard Glipizide yielded a significant signal in either positive 
or negative mode, so the same internal standard could be used for all samples for both 
method validation and dosed mice brain samples. 
In multiple reaction monitoring (MRM) the most significant product ions found for 
MCC950, with a molecular weight of 404.5 (C20H24N2O5S), were: 204 ([M-200]-) and 80 
([M-324]-) m/z. The product ion used for quantification was 204 and the retention time for 
Figure 41. Retention times and extracted ion intensity for product ions of JC-171 
(GA4), MCC950, and Glipizide. Product ions for MCC950 and GA4 used for 
quantification are depicted by red peaks. 
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product ions were 3.110 minutes. The product ions monitored for GA4, with a molecular 
weight of 385.8 (C16H17ClN2O5S), were: 304 ([M + H-80]+) and 169 ([M + H-215]+) m/z. 
The product ion used for quantification was 169 and the retention time for product ions 
were 2.590 minutes. For Glipizide, with a molecular weight of 445.5 (C21H27N5O4S), either 
product ion 319 ([M – H-126]-) for negative ionization ESI mode or 321([M + H-125]+) for 
positive ionization mode was used. For Glipizide product ion, the retention time was 2.520 
minutes (Figure 41). The product ion with the highest signal was monitored for 
quantification purposes and the other product ion was monitored for quality control. 
Additionally, to determine if carry over would occur between samples a double blank 
sample, a sample with neither internal standard or analyte, was used. It was determined 
that there was minimal carry over between samples (Figure 42). 
Figure 42.  Multiple reaction monitoring for GA4, MCC950, and Glipizide in double 
blank sample to determine carry over. 
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3.6.2. Validation 
The extraction method had to be adjusted to account for both compounds being 
run through different ionization ESI modes. When testing different extraction solvents for 
extracting the analytes from brain tissue, it was determined that 1% FA in ACN was most 
effective for compound GA4.  
The extraction solvent 1%FA in ACN could only be used for both if the solvent was 
completely evaporated after filtering through a phospholipid filter plate (Biotage, Uppsala, 
121617A.rdb (GA41): "Linear Through Zero" Regression ("No" weighting): y = 0.225 x (r = 0.9991)
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Figure 43. Calibration curve of GA4 from brain tissue at concentrations: 2.5, 25, 125, 
250, 500, 1,250 ng/g. Equation (y = 0.225 x (r=0.9991)) 
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Sweden). Evaporation of solvent removed FA from sample and prevented negative ion 
suppression of MCC950. The solvent used for reconstitution also required optimization to 
use for both analytes. MCC950 was more flexible in terms of solvent used for  
reconstitution and could be done with ACN or methanol. However, without pure methanol 
or a 90:10 water/methanol reconstitution solvent, GA4 was retained on the column. For 
simplicity methanol was the chosen solvent for reconstitution.  
To accurately quantify analyte in brain tissue, a six-point calibration curve for both 
compounds (2.50-1,250 ng/g) were run after extraction from brain tissue (Figure 43, 44). 
121617A.rdb (MCC950): "Linear Through Zero" Regression ("No" weighting): y = 4.92 x (r = 0.9987)
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Figure 44. Calibration curve of MCC950 from brain tissue at concentrations: 2.5, 25, 
125, 250, 500, 1,250 ng/g. Equation ( y = 4.92 x (r=0.9987)) 
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The calibration curves were reproducible with a coefficient of determination for MCC950 
(R2)= (0.9920-0.9998) and for GA4 (R2)= (0.9940-0.9982). Neither linear regression 
equation was weighted. The relative residuals remained below 20% for each point on 
either calibration curve. 
 The with-in assay precision and bias were determined for each 3 runs. Each run 
had a calibration curve and 3 repeats of low (7.5 ng/g), medium (150 ng/g), and high 
(1,000 ng/g) samples. Both the % CV (precision) and % Bias (accuracy) remained below 
20% and within allowable error with 2 exceptions (Table 1-3). The with-in %CV for 
MCC950 fell in the range of 2.050- 7.100% and the %CV for GA4 fell in the range of 
0.5300-6.130%. The % Bias for MCC950 fell in the range of 0-14.90% with the exception 
of the low (7.5 ng/g) sample in run 3. The %Bias for GA4 fell in the range of 10.20-18.90% 
with the exception of the high (1,000 ng/g) sample in run 3. The MCC950 low QC samples 
(7.5 ng/g) ran slightly higher than what was accurate. GA4 high QC samples (1,000 ng/g) 
were significantly lower than what the values should have read, indicating human error in 
sample preparation so this data was not included in in-between assay %CV and %Bias 
calculations. 
The in-between precision and accuracy was then calculated from pooled data. The 
in-between %CV among low, medium, and high samples from MCC950 ranged between 
11-15%. The %Bias for MCC950 fell in the range of 1.000-7.000% (Table 4). For GA4, 
the in-between %CV among low, medium, and high samples ranged from 2.000-5.000%. 
The %Bias for GA4 fell within 14.00-17.00% (Table 5).  All %CV and %Bias fell with-in 
allowable error ≤ 20%, demonstrating that the method was sufficient for use in 
determining the concentration of these compounds from tissue samples. 
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Run 1   
Run 1 QC : 
MCC950    
Sample Name MCC950 GA4 Repeat Low (7.5 ng/g) 
Mid (150 
ng/g) 
High 
(1000 
ng/g) 
Test 253.5 116.5 1 7.550 135.5 1035 
2.5 ng/g 
MCC950 & GA4 4.695 1.015 2 6.500 136.0 1140 
25 ng/g MCC950 
& GA4 22.45 8.300 3 7.150 129.0 1125 
125 ng/g 
MCC950 & GA4 119.5 132.0 Mean 7.067 133.5 1100 
250 ng/g 
MCC950 & GA4 224.5 287.5 SD 0.4330 3.189 46.37 
500 ng/g 
MCC950 & GA4 515.0 520.0 %CV 6.123 2.388 4.215 
1250 ng/g 
MCC950 & GA4 1720 1235 %Bias -5.778 -11.00 10.00 
Blank No Peak No Peak      
Double Blank No Peak No Peak 
Run 1 QC: 
GA4     
High QC (1000 
ng/g MCC950 & 
GA4) 1035 1145 Repeat Low (7.5 ng/g) 
Mid (150 
ng/g) 
High 
(1000 
ng/g) 
Low QC (7.5 
ng/g MCC950 & 
GA4) 7.550 8.700 1 8.7 155.5 1145 
High QC (1000 
ng/g MCC950 & 
GA4) 1140 1175 2 8.7 174.5 1175 
Low QC (7.5 
ng/g MCC950 & 
GA4) 6.500 8.700 3 8.6 166.0 1125 
High QC (1000 
ng/g MCC950 & 
GA4) 1125 1125 Mean 8.667 165.3 1148 
Low QC (7.5 
ng/g MCC950 & 
GA4) 7.150 8.600 SD 0.04710 7.771 20.55 
Mid QC (150 
ng/g MCC950 & 
GA4) 135.5 155.5 %CV 0.5440 4.700 1.789 
Mid QC (150 
ng/g MCC950 & 
GA4) 136.0 174.5 %Bias 15.56 10.22 14.83 
Mid QC (150 
ng/g MCC950 & 
GA4) 129.0          
r 0.9990 0.9990         
r2 0.9980 0.9980         
 
Table 1.  Run 1 calibration curve and low, medium, and high QC samples. 
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Run 2 
    
Run 2 QC 
: MCC950       
Sample Name MCC950 GA4 Repeat Low (7.5 ng/g) 
Mid (150 
ng/g) 
High 
(1000 
ng/g) 
2.5 ng/g 
MCC950 & GA4 
1.740 0.8700 1 8.000 143.5 1100 
25 ng/g MCC950 
& GA4 
21.55 8.200 2 6.900 144.0 1210 
125 ng/g 
MCC950 & GA4 
112.5 129.5 3 7.600 137.0 1195 
250 ng/g 
MCC950 & GA4 
182.0 205.0 Mean 7.500 141.5 1168 
500 ng/g 
MCC950 & GA4 
510.0 475.5 SD 0.4550 3.189 48.70 
1250 ng/g 
MCC950 & GA4 
1260 1270 %CV 6.061 2.253 4.169 
Blank No Peak No Peak %Bias 0 -5.667 16.83 
Double Blank No Peak No Peak         
High QC (1000 
ng/g MCC950 & 
GA4) 
1100 1185 
Run 2 
QC: GA4 
    
  
Low QC (7.5 
ng/g MCC950 & 
GA4) 
8.000 8.950 Repeat Low (7.5 ng/g) 
Mid (150 
ng/g) 
High 
(1000 
ng/g) 
High QC (1000 
ng/g MCC950 & 
GA4) 
1210 1215 1 8.950 160.5 1185 
Low QC (7.5 
ng/g MCC950 & 
GA4) 
6.900 8.950 2 8.950 180.0 1215 
High QC (1000 
ng/g MCC950 & 
GA4) 
1195 1165 3 8.850 171.0 1165 
Low QC (7.5 
ng/g MCC950 & 
GA4) 
7.600 8.850 Mean 8.917 170.5 1188 
Mid QC (150 
ng/g MCC950 & 
GA4) 
143.5 160.5 SD 0.04710 7.969 20.55 
Mid QC (150 
ng/g MCC950 & 
GA4) 
144.0 180.0 %CV 0.5290 4.674 1.729 
Mid QC (150 
ng/g MCC950 & 
GA4) 
137.0 
171.0 
%Bias 18.89 13.67 18.83 
r 0.9990 0.9990         
r2 0.9970 0.9980         
Table 2. Run 2 calibration curve and low, medium, and high QC samples. 
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Run 3 
    
Run 3 QC : 
MCC950 
      
Sample Name MCC950 GA4 Repeat 
Low (7.5 
ng/g) 
Mid (150 ng/g) 
High (1000 
ng/g) 
2.5 ng/g 
MCC950 & GA4 
3.500 21.20 1 8.920 162.0 862.0 
25 ng/g 
MCC950 & GA4 
38.40 20.80 2 9.040 172.2 864.0 
125 ng/g 
MCC950 & GA4 
121.8 88.20 3 10.40 177.2 826.0 
250 ng/g 
MCC950 & GA4 
258.0 159.6 Mean 9.453 170.5 850.7 
500 ng/g 
MCC950 & GA4 
490.0 212.0 SD 0.6710 6.325 17.46 
1250 ng/g 
MCC950 & GA4 
1252 1322 %CV 7.100 3.711 2.053 
Blank No Peak 4.940 %Bias 26.04 13.64 -14.93 
Double Blank No Peak No Peak         
High QC (1000 
ng/g MCC950 & 
GA4) 
862.0 218.0 
Run 3 QC: 
GA4 
    
  
Low QC (7.5 
ng/g MCC950 & 
GA4) 
8.920 7.660 Repeat 
Low (7.5 
ng/g) 
Mid (150 ng/g) 
High (1000 
ng/g) 
High QC (1000 
ng/g MCC950 & 
GA4) 
864.0 216.0 1 7.660 178.2 218.0 
Low QC (7.5 
ng/g MCC950 & 
GA4) 
9.040 8.520 2 8.520 179.0 216.0 
High QC (1000 
ng/g MCC950 & 
GA4) 
826.0 212.0 3 8.880 172.0 212.0 
Low QC (7.5 
ng/g MCC950 & 
GA4) 
10.40 8.880 Mean 8.353 176.4 215.3 
Mid QC (150 
ng/g MCC950 & 
GA4) 
162.0 178.2 SD 0.5120 3.128 2.494 
Mid QC (150 
ng/g MCC950 & 
GA4) 
172.2 179.0 %CV 6.127 1.773 1.158 
Mid QC (150 
ng/g MCC950 & 
GA4) 
177.2 
172.0 
%Bias 11.38 17.60 -78.47 
r 0.9999 0.9972         
r2 0.9998 0.9944         
 
Table 3. Run 2 calibration curve and low, medium, and high QC samples. 
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MCC950 QC Total   
Run Repeat Low (7.5 ng/g ) Mid (150 ng/g) High (1000 ng/g) 
  1 7.550 135.5 1035 
1 2 6.500 136.0 1140 
  3 7.150 129.0 1125 
  1 8.000 144.0 1100 
2 2 6.900 144.0 1210 
  3 7.600 137.0 1195 
  1 8.920 162.0 862.0 
3 2 9.000 172.0 864.0 
  3 10.40 177.2 826.0 
  Mean 8.010 148.5 1040 
  SD 1.170 16.50 142.3 
  %CV 15.00 11.00 14.00 
  %Bias 7.000 -1.000 4.000 
  Linearity 
2.5ng/g - 1250 
ng/g  r2  0.9920-0.9998 
 
 
 
 
 
 
 
 
 
 
GA4 QC Total   
Run Repeat Low (7.5 ng/g ) Mid (150 ng/g) High (1000 ng/g) 
  1 8.700 155.5 1145 
1 2 8.700 174.5 1175 
  3 8.600 166.0 1125 
  1 8.950 161.0 1185 
2 2 8.950 180.0 1215 
  3 8.850 171.0 1165 
  1 7.660 178.2   
3 2 9.000 179.0   
  3 8.880 172.0   
  Mean 8.650 170.7 1168 
  SD 0.3800 8.060 28.67 
  %CV 4.000 5.000 2.000 
  %Bias 15.00 14.000 17.00 
  Linearity 2.5ng/g - 1250 ng/g   r2  0.9940-0.9982 
Table 4. In-between precision and bias for low, medium, and high MCC950 samples. 
 
Table 5. In-between precision and bias for low, medium, and high GA4 samples. 
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3.6.3. Application and Discussion 
To determine the BBB penetration of GA4 and compare to the more potent 
MCC950, brain samples from mice administered GA4 and MCC950 at 0.1 mg/kg and 0.5 
mg/kg via intraperitoneal injection, were collected after 2 h of compound administration. 
Following the optimized extraction method and established LC-MS method, the samples 
were weighed, homogenized, and extracted. The estimation of concentrations detected 
from tissue were calculated based on calibration curves established (Table 6). 
On average the concentration of drug extracted from the brain tissue of mice given 
intraperitoneal injections of 0.1 mg/kg of MCC950 was 0.7530 ng/g. This value fell outside 
the calibration curve for this compound so this value was from extrapolation and the 
likelihood of accuracy for this value was lower than interpolated values. However, this 
does not change the overall conclusion of these results combined. Comparatively, from 
mice given the same dose of GA4, an average of 9.200 ng/g of drug was detected in the 
brain tissue.  
When mice were injected with 0.5 mg/kg of GA4, the average detected 
concentration in the brain tissue was 18.12 ng/g. However, the difference between the 2 
samples was high. Given the amount of GA4 detected in mice given 0.1 mg/kg, the higher 
value seemed more reasonable. The reason for this difference did not appear to be an 
error in extraction or an issue with the method; when the other half of the brain from 
mouse #7 and #8 was tested the same distinct difference in concentration of drug 
detected was observed. This indicated that the reason for this difference may have been 
the sample itself. In mice given the same dose of MCC950, the detected concentration 
from the brain tissue was only and average of 3.050 ng/g. So, despite this discrepancy in 
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the brain samples of mice injected with GA4, the amount detected was still higher than 
the concentration of MCC950 detected from mice given the same dose. GA4 (JC-171), 
not only demonstrated BBB penetration but was superior to the BBB penetration of the 
more potent NLRP3 inhibitor MCC950. This may partially explain the reason for 
comparable therapeutic in vivo activity in mouse model of MS. 
Sample # and Drug Dose MCC905 ng/g GA4 ng/g 
1-vehicle ND ND 
2-vehicle ND ND 
3-MCC950 0.5mg/kg 3.240 ND 
4-MCC950 0.5mg/kg 2.860 ND 
5-MCC950 0.1mg/kg 0.6460 ND 
6-MCC950 0.1mg/kg 0.8600 ND 
7-GA4 0.5mg/kg ND 29.00 
8-GA4 0.5mg/kg ND 7.240 
9-GA4 0.1mg/kg ND 10.84 
10-GA4 0.1mg/kg ND 7.560 
ND = None Detected   
 
 
 
 
 
 
 
Table 6. Concentration of drug detected from the brain tissue of mice 
given the indicated doses of drug by intraperitoneal injection. 
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Chapter 4: Methods and Materials 
4.1 MST 
4.1.1 NLRP3 (LRR), NLRP3 (full length), and NLRP3 (K232A) 
The proteins used were either recombinant mouse NLRP3 (LRR) with n-terminal 
His-tag (amino acids: 671-1033) (LS Bio, Seattle, WA), recombinant human NLRP3 with 
n-terminal His-tag (amino acids: 2-1036) (BPS bioscience, San Diego, CA), or 
recombinant mutant human NLRP3 (K232A) with n-terminal His-tag (amino acids: 2-
1036) (BPS bioscience, San Diego, CA).  Protein was labeled with His-tag RED-tris-NTA 
monolith protein labeling kit according to manufacturer’s instructions (Nanotemper, 
München, Germany).  The labeling kit has high efficiency and removal of excess dye or 
purification is not necessary. Monolith NT. Automated machine was used for MST assay 
(Nanotemper, München, Germany). 10ul of the NT-647 labeled protein was added to 12 
wells of a 384 well plate (Corning, Corning, NY) at a final concentration of 50 nM with the 
addition of 10 µl of 12 different concentrations ligand and a final concentration of 5% 
DMSO in each well. MST premium-coated capillary chip was inserted into the 12 wells 
and then placed into the MST machine. The MST excitation was set to 40% for sufficient 
fluorescence counts and the MST power was set to medium for the best signal to noise 
ratio. All binding data used passed MST quality checks such as: no aggregation, 
consistent initial fluorescence, and no photo-bleaching. 
4.1.2 ASC 
The protein used was recombinant human ASC/TMS1 with GST tag (Novus, 
Littleton, CO). Protein was labeled with cysteine reactive monolith protein labeling kit red-
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maleimide and purified according to manufacturer’s instructions (Nanotemper, München, 
Germany). The fractions were run through UV-1800 Shimazdu spectrophotometer the 
absorption at wavelengths at 280 and 680nm were compared by using the molar 
absorbance of the dye (250,000 M−1cm−1) to calculate degree of labeling and the molar 
extinction coefficient of the protein (67123) to calculate the protein concentration in each 
fraction (Shimazdu, Kyoto, Japan).  
 
 
The best fraction with nearly equal signal from protein and fluorescent tag, fraction 5, was 
used in MST experiments (Figure 45). Monolith NT. Automated machine was used for 
MST assay (Nanotemper, München, Germany). 10ul of the NT-647 labeled ASC protein 
was added to 12 wells of a 384 well plate (Corning, Corning, NY) at a final concentration 
of 10nM with the addition of 10 µl of 12 different concentrations ligand and a final 
Figure 45. Purified fractions from fluorescently tagged (NT-647) ASC protein. 
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concentration of 5% DMSO in each well. MST premium-coated capillary chip was inserted 
into the 12 wells and then placed into the Monolith NT.Automated MST machine 
(Nanotemper, München, Germany). The MST excitation was set to 95% for sufficient 
fluorescence counts and the MST power was set to medium for the best signal to noise 
ratio. 
4.2 ADP-Glo 
3 µl of recombinant human NLRP3 aa 2-1036 80117 (BPS Bioscience, San Diego, 
CA) was incubated in a 384 well white plate (Greiner Bio-one, Kremsmünster, Austria) at 
a concentration of 7ng/ul with 1 µl of the given concentration of compounds mentioned 
for 15 min at 37 °C in reaction buffer 20 mM Tris-HCl (pH 7.8), 20 mM MgCl2, 133 mM 
NaCl, 3 mM KCl, 0.56 mM EDTA, and 2% DMSO, following the reference protocol.144 250 
μM of ultra-pure ATP, provided by ADP-Glo kit (Promega, Madison, WI), was added to 
each well and further incubated at 37 °C for 40 minutes. Due to the small quantities added 
in each step, protein, compound, and ATP were all added via acoustic liquid handling 
technology, Echo 555 (Labcyte, San Jose, CA). Luminescent ADP-Glo Kinase Assay kit 
was used to detect and quantify ADP produced by ATP hydrolysis of the ATPase of 
NLRP3 per manufacturer’s protocol (Promega, Madison, WI). Clariostar multi-mode 
microplate reader was used to quantify luminescence produced from each reaction (BMG 
Labtech, Ortenburg, Germany). 
4.3 Molecular Modeling 
With no crystal structure of NBD domain of NLRP3, homology models were 
generated from template crystal structure of NLRC4 (PDB code 4KXF)158. Template 4KXF 
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was chosen based on sequence similarity in BLAST search of FASTA sequence of NBD 
(aa 220-536) of human NLRP3 (Uniprot code Q96P20). Sequence alignment was done 
via EMBOSS needle pairwise sequence alignment (EMBL-EBI, Hinxton, UK).162 100 
models were generated using MODELLER v 9.17.157 Models were compared via 
Ramachandran plots. The model 70 was chosen based on acceptable Ramachandran 
plot and further validation by docking ADP from the crystal structure of NLRC4 back into 
the nucleotide binding pocket. Model 70 was minimized using SYBL-X 2.1.1(Tripos 
Associates, St. Louis, MO) using Tripos force field and Gasteiger-Hückel charges. 
Compounds were docked into a chosen model using GOLD 5.4 (The Cambridge 
Crystallographic Data Centre, Cambridge, England). Pictures of protein and docked 
ligands were generated using PyMol (Schrödinger, LLC, New York, NY). HINT scores 
were calculated to determine if hydropathic interactions were favorable.160  
4.4 NLRP3 production 
4.4.1 Plasmid and General Procedure 
Plasmid pEGFP-C2-NLRP3 ( catalog # 73955)  was purchased from nonprofit plasmid 
repository addgene.13 Purification of plasmid from bacteria with done with Qiagen mini-
prep per manufacturer’s protocol (Qiagen, Hilden, Germany). When PCR was attempted 
using forward primer with added histidine tag on amino terminus (5’ 
ggatgctagcatgcaccatcaccatcaccatgcaagcacccgctgcaagctggccagg 3’) and reverse primer 
(5’ cgggatccctaccaagaaggctcaaagacgacggtcag 3’) the correct sequence could not be 
produced from PCR. To get correct sequence extra restriction sites had to be used to 
divide the sequence to be cloned into 2 parts. Restriction sites used included: NheI at 
amino terminus, BamHI in the middle of the sequence, and XhoI at the carboxy terminus. 
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Primer’s to introduce sequences and clone protein sequence in 2 parts were purchased 
from Invitrogen: NheF (5’ ggatgctagcatgcaccatcaccatcaccatgcaagcacccgctgcaagctggc 
cagg 3’), BamR(5’ ggggatcctggaacgttcgtccttccttccttttcctc 3’), BamF (5’ caggatcccgtttgaa 
gcttcccagccgagacgtg 3’), and XhoR (5’ gcctcgagctaccaagaaggctcaaagacgacgg 3’) 
(Invitrogen, Carlsbad, CA) . 
4.4.2 PCR  
DreamTaq Green PCR Master mix (2x) (ThermoFisher Scientific, Waltham, MA) 
was thawed, vortexed and quickly centrifuged. A PCR tube was cooled down on ice and 
to it was added: 25 µl of DreamTaq Green PCR Master mix, 0.5µM of each forward 
primer, 0.5 µM of each reverse primers and 0.5 µg of the template DNA, and enough 
nuclease-free DI water to bring the total volume up to 50 µl. Sample was vortexed and 
spun down. A thermocycler was then used for 2 minutes at 95°C for initial denaturing of 
DNA. After initial denaturing, 30 cycles of denaturation at 95°C for 30 seconds, annealing 
at 72°C for 30 seconds, then extension at 72°C for 1 minute. For the final extension, 1 
cycle was done at 72°C for 10 minutes (ThermoFisher Scientific, Waltham, MA). 10 uL of 
PCR mixture was directly added to gel to analyze via agarose gel electrophoresis 
according to protocol (Agarose Gel Electrophoresis protocol, Addgene, Cambridge, MA). 
PCR products were recovered using Qiaquick gel extraction kit following the 
manufacturer’s protocol (Qiagen, Hilden, Germany). PCR products were sent to Eurofins 
Scientific were utilized to determine the sequence (Eurofins Scientific, Brussels, Belgium). 
4.4.3 Transformation  
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Purified PCR products and vector pcDNA 3.1/Hygro were then digested with the 
appropriate enzymes and each piece separately ligated into vector with DNA ligase 
according to manufacturer’s protocol (DNA ligation kit, ThermoFisher Scientific, Waltham, 
MA). BL21 (DE3) competent E. coli cells were thawed on ice for 10 minutes. 5 uL of 5 ng 
of plasmid was added to thawed bacteria cells and mixed by gently tapping. Vials were 
left to incubate on ice for 30 minutes. Vials of bacteria and plasmid were heat shocked by 
placing vial into a 42°C water bath for 30 seconds. Vial was then placed on ice. 250 uL of 
pre-warmed SOC medium was then added to vial. Vial was set to incubate at 37°C on 
cell shaker for 1 hour at 225 rpm (ThermoFisher Scientific, Waltham, MA). 50 uL was 
plated on pre-warmed plate at 37°C, LB agar selection plates containing 100 ug/ml of 
ampicillin, and the rest in the other plate. Plates were inverted and incubated at 37°C 
overnight. Qiagen mini-prep was used to collect plasmid from the bacteria (Qiagen, 
Hilden, Germany). 
4.4.4 Transfection  
6 x 107 HEK293 cells were seeded into 30mL of Expi293TM expression medium 
and incubated at 37 °C in a humidified environment with 8% CO2 with cell shaker set to 
125 rpm (ThermoFisher Scientific, Waltham, MA). A 100 µl aliquot of the cell solution was 
added to 0.4% solution of trypan blue dye in PBS at a 1:1 ratio. This trypan blue/cell 
solution was then loaded onto a hemocytometer to determine cell density and viability. 
Once the cells reached a density between 3-5 x 106 /mL cell density and were still above 
95% viability the cells were ready for transfection. 7.5 x 107 cell were then diluted with 
25.5 mL of Expi293TM expression medium in a 125 mL flask. 30 µg of purified plasmid 
was then suspended in 1.5 mL of Opti-MEM reduced serum medium and gently mixed. 
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81 µl of ExpiFectamine TM 293 reagent was then diluted in Opti-MEM I medium to final 
volume of 1.5 mL, this was then mixed gently and incubated at room temperature for 5 
minutes. The plasmid and ExpiFectamine TM reagent were then mixed together and left to 
incubate at room temperature for 20 minutes. The plasmid/ ExpiFectamine TM mix was 
then carefully added to the flask of cells in a dropwise manner. The cells were then left to 
incubate for 20 hours at 37 °C in a humidified environment with 8% CO2 with cell shaker 
set to 125 rpm. After 20 hours, 150 µl of ExpiFectamineTM transfection enhancer 1 and 
1.5 mL of enhancer 2 were added to the flask of cell solution (Transfecting Expi293FTM 
Cells protocol, ThermoFisher Scientific, Waltham, MA). Since the best time for protein 
expression depends of the protein, 2 1 mL fractions of the cell solution were collected 
every day for 4 days. 1 of the 1mL fractions from each day was spun down at 10,000 g 
for 10 minutes and supernatant removed. Pellets were frozen at -20 °C for 20 minutes. 
Cells were lysed with NP-40 RIPA lysis buffer and protease inhibitor. Protein 
concentration was calculated via the Bradford assay.  
4.4.5 SDS-PAGE  
HEK 293 cells were lysed with buffer cooled down to 0 °C containing: 150 mM 
NaCl, 1% NP-40, 50 mM Tris (pH 8) and SIGMAFASTTM protease inhibitor cocktail 
(Sigma-Aldrich, St. Louis, MO). 350 µl of lysis buffer was added to each aliquot of ~5 
million cells for each of the 4 days cells were collected. Mixture was left on ice for 15 
minutes. Mixture was then sonicated for 5 seconds and left on ice for 15 minutes. Cell 
lysates were then centrifuged at 15,000 rpm at 4°C for 20 minutes. The Bradford assay 
was then employed to estimate protein concentration of cell lysates. Sample buffer was 
made with 50 µl of 2-Mercaptoethanol and 950 µl of 2x Laemmli Sample buffer (BIO-
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RAD, Hercules, CA). 15 µl of cell lysates were then diluted with 15 µl of sample buffer 
and boiled at 90°C for 10 minutes in a water bath and then placed on ice. Cell lysates 
were spun down at 4°C at 2,350 rpm for 3 minutes. Diluted sample was injected into 
CriterionTM 4-15% Tris-HCl 18 well Precast gel (BIO-RAD, Hercules, CA). Gel was run 
with BIO-RAD CriterionTM Cell electrophoresis set to 100 V for 2 hours(BIO-RAD, 
Hercules, CA). 
4.4.6 Immunoblot  
Immun-Blot PVDF membrane was soaked in methanol (BIO-RAD, Hercules, CA). 
CriterionTM blotter pads were then soaked in Tris/Glycine transfer buffer. Protein was 
transferred to membrane with CriterionTM blotter set to 0.4 A for 2 hours. Blot was then 
submerged in blocking solution (5% nonfat dry milk, and 50 mL TBST solution) for 1 
hour. Anti-NLRP3 antibody was thawed to room temperature. 1 mg/mL of antibody was 
diluted 1:800 in 5% nonfat dry milk TBST solution. Blot was washed with TBST solution 
(Tris buffered saline with 0.1% Tween-20 (Sigma-Aldrich, St. Louis, MO)) 3 times. 
Secondary antibody, anti-rabbit IgG HRP-linked antibody, was thawed and diluted 
1:1000 in 5% nonfat dry milk TBST solution and applied to membrane and incubated at 
4°C overnight. Blot was washed with TBST solution 3 times and chemiluminescent 
substrate solution was added to the blot and labeled protein visualized with GE gel 
imager (Amersham, Little Chalfont, UK). 
4.5 LC-MS 
4.5.1 Materials 
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The plasma purchased for method validation was C57BL/6 mouse K2EDTA plasma 
(BioreclamationIVT, Westbury, NY). Brains from C57BL/6 mice dosed with known 
concentrations of compound by intraperitoneal injection were obtained from collaborators 
(Dr. Xiang-Yang Wang Lab). The brain tissue used for controls and calibration curve. To 
remove protein and phospholipids after extraction ISOLUTE PPT+ 96 well filter plate was 
used (Biotage, Uppsala, Sweden). LC-MS samples were run using a Shimadzu LC-30AD 
pump, Shimadzu SIL-30AC autosampler (Shimadzu, Kyoto, Japan), with an AB SCIEX 
linear ion trap quadrupole 6500+ (SCIEX, Framingham, MA). The column used to achieve 
separation was a Xterra MS C18 3.5 um 2.1x100mm (Waters, Manchester, UK). 
4.5.2 Brain extraction  
 ½ of brain from mice dosed with drug or control mice was homogenized in PBS at 
a ratio of 1.5mL of PBS per 0.5g of brain. 500uL of brain homogenate from each sample 
was spiked with 150ul of 50ng/ml of Glipizide in methanol. Samples were then extracted 
with 500ul of ACN with 1% FA and vortexed then left to sit on ice for 15 min. Samples 
were then centrifuged at highest rpm for 10 min at 4°C.  Supernatant was collected and 
then samples were extracted a second time with 500ul of ACN with 1% FA and the same 
protocol. Supernatant was combined and then filtered through phospholipid/protein filter 
plate, solvent evaporated and then reconstituted with 150ul of methanol and injected onto 
LC-MS. 
4.5.3 LC-MS Calibration and QC 
 Standard concentrations and QC samples of each compound were prepared in 
PBS and then added to blank mouse plasma or blank mouse brain tissue for the correct 
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concentration of ng of drug to g of brain or plasma. The samples were homogenized and 
then spiked with 150ul of 50ng/ml Glipizide internal standard and extracted with 1000uL 
of ACN with 1% FA and left to sit on ice for 15 min. Samples were centrifuged at highest 
rpm for 10min at 4°C, and then supernatant was filtered through phospholipid/protein 
filter. Filtrate was evaporated and then reconstituted with 150ul of methanol and then ran 
through LC-MS. The final calibration standard concentrations were: 1,250, 500, 250, 125, 
25, 2.5 ng/g. The final QC drug concentrations were 7.5, 150 and 1000 ng/g. 
4.5.4 LC-MS Parameters 
JC-171 samples were run in positive ion mode and MCC950 was run in negative. 
Mobile phase A consisted of water with 10mM ammonium acetate and mobile phase B 
was methanol. Injection volume was 2uL with a flow rate of 300 uL/min. The optimized 
LC-MS parameters for GA4 and internal standard Glipizide were set to: ionspray voltage 
(IS) +4500 V, temperature 500 °C, nebulizer gas (GS1) 60, TurboIonSpray gas (GS2) 50, 
collision-activated dissociation (CAD) gas medium, declustering potential (DP) +60 V, 
and entrance potential (EP) +10 V. Collision cell exit potential (CXP) settings for GA4 was 
10.5 eV. The MRM (Multiple Reaction Monitoring) transitions for GA4 
were m/z 385 → 304 with CE of 21 eV and 385 → 169 with collision energy (CE) of 32 
eV. For Glipizide, the MRM was m/z 446 → 321 with CE of 20 eV. Dwell times for both 
GA4 and Glipizide were 100 milliseconds. 
 The optimized LC-MS parameters for MCC950 and internal standard 
Glipizide were set to: ionspray voltage (IS) -4500 V, temperature 500 °C, nebulizer gas 
(GS1) 60, TurboIonSpray gas (GS2) 50, collision-activated dissociation (CAD) gas 
medium, declustering potential (DP) -60 V, and entrance potential (EP) -10 V. Collision 
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cell exit potential (CXP) settings for MCC950 was -18.5 eV. The MRM (Multiple Reaction 
Monitoring) transitions for MCC950 were m/z 403.5 → 80 with CE of -45 eV and 
403.5 → 204 with collision energy (CE) of -30 eV. For Glipizide, the MRM was 
m/z 445 → 319 with CE of -20 eV. Dwell times for both MCC950 and Glipizide were 100 
milliseconds. 
4.5.5 LC-MS Analysis 
MRM data acquisition, chromatographic peak integration, data regression using 
peak area ratios of the analyte to internal standard, and chromatographic review were 
performed using Sciex Analyst, version 1.6.3 software. Linear regression of calibration 
curve for MCC950 had an r2 of 0.992-0.9998 and 0.994-0.9982 for GA4. The unweighted 
linear regression equation calculated from the calibration curve of each compound   was 
used to predict the concentration of analyte in each brain sample. The CV was calculated 
in excel by dividing the SD by the mean. 
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Conclusion 
To conclude, our studies demonstrated direct binding of JC-171 to the NLRP3 
protein. The binding affinity of JC-171 to the NLRP3 protein was not significantly altered 
in mutant NLRP3 (K232A).  Additionally, ATPase studies indicated that JC-171 and its 
analogs did not interfere with the ATPase activity of NLRP3. This data supports the notion 
that JC-171 may bind to the NACHT domain of NLRP3 in a site that is distinct from the 
ATP binding site. Molecular modeling studies of JC-171 to the homology model of the 
NACHT domain of the NLRP3 protein indicated a possible binding site for JC-171 and 
analogs next to the ATP binding pocket, further supporting the assertion that JC-171 
binds to the NACHT domain. LC-MS analysis of brain tissue in mice dosed with MCC950 
and JC-171 confirmed that JC-171 not only penetrates the BBB but demonstrated better 
BBB penetration when compared to MCC950. This data, as well as the binding data 
suggesting an alternative MOA, might aid in the explanation of JC-171s comparable 
efficacy in ameliorating the progression of disease pathology in EAE, mouse model of 
MS, with MCC950, a compound with significantly higher inhibitory potency in vitro.  
Together, these results strongly support that our compounds inhibit the NLRP3 
inflammasome by directly interacting with the NLRP3 protein, a novel MOA when 
compared to other known inhibitors of the NLRP3 inflammasome. These results strongly 
encourage further development of such inhibitors as potential therapeutics for 
neurodegenerative diseases.
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